https://trial.medpath.com/news/targeting-the-m6a-writer-mettl3-shows-neuroprotective-potential-in-neuroinflammation 2026-08-08T16:48:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/targeting-the-m6a-writer-mettl3-shows-neuroprotective-potential-in-neuroinflammation 2026-08-08T16:48:17+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-extends-felzartamab-kidney-transplant-rejection-trial-into-four-year-long-term-safety-study 2026-08-08T15:51:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-extends-felzartamab-kidney-transplant-rejection-trial-into-four-year-long-term-safety-study 2026-08-08T15:51:18+00:00 hourly 0.9 https://trial.medpath.com/news/cell-based-therapy-shows-functional-improvement-in-sjogren-s-syndrome-patient-with-severe-neurological-complications 2026-08-08T15:51:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cell-based-therapy-shows-functional-improvement-in-sjogren-s-syndrome-patient-with-severe-neurological-complications 2026-08-08T15:51:13+00:00 hourly 0.9 https://trial.medpath.com/news/global-optogenetics-actuators-and-sensors-market-to-reach-usd-4-2-billion-by-2036-driven-by-neuroscience-research-and-federal-funding 2026-08-08T15:49:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-optogenetics-actuators-and-sensors-market-to-reach-usd-4-2-billion-by-2036-driven-by-neuroscience-research-and-federal-funding 2026-08-08T15:49:42+00:00 hourly 0.9 https://trial.medpath.com/news/nyu-researchers-advance-blood-based-biomarker-testing-for-early-alzheimer-s-detection-identifying-disease-up-to-a-decade-before-symptoms 2026-08-08T15:49:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nyu-researchers-advance-blood-based-biomarker-testing-for-early-alzheimer-s-detection-identifying-disease-up-to-a-decade-before-symptoms 2026-08-08T15:49:41+00:00 hourly 0.9 https://trial.medpath.com/news/salmonella-outbreak-linked-to-mexican-jalapenos-sickens-345-across-27-states-triggers-usda-public-health-alert 2026-08-08T14:47:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/salmonella-outbreak-linked-to-mexican-jalapenos-sickens-345-across-27-states-triggers-usda-public-health-alert 2026-08-08T14:47:45+00:00 hourly 0.9 https://trial.medpath.com/news/surrozen-submits-ind-for-szn-8141-a-bifunctional-wnt-agonist-vegf-antagonist-for-diabetic-macular-edema 2026-08-08T13:48:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/surrozen-submits-ind-for-szn-8141-a-bifunctional-wnt-agonist-vegf-antagonist-for-diabetic-macular-edema 2026-08-08T13:48:13+00:00 hourly 0.9 https://trial.medpath.com/news/a-minister-s-cervical-cancer-journey-kiri-allan-on-diagnosis-fertility-loss-and-the-public-health-system 2026-08-08T13:47:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/a-minister-s-cervical-cancer-journey-kiri-allan-on-diagnosis-fertility-loss-and-the-public-health-system 2026-08-08T13:47:43+00:00 hourly 0.9 https://trial.medpath.com/news/qc-ware-and-ionq-demonstrate-high-precision-hybrid-quantum-workflow-for-drug-discovery 2026-08-08T13:47:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qc-ware-and-ionq-demonstrate-high-precision-hybrid-quantum-workflow-for-drug-discovery 2026-08-08T13:47:34+00:00 hourly 0.9 https://trial.medpath.com/news/real-time-live-cell-observation-platform-could-transform-cancer-drug-discovery-and-precision-medicine 2026-08-08T12:48:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-time-live-cell-observation-platform-could-transform-cancer-drug-discovery-and-precision-medicine 2026-08-08T12:48:24+00:00 hourly 0.9 https://trial.medpath.com/news/mediar-therapeutics-enters-collaboration-with-ono-pharma-to-develop-novel-antibody-therapeutics-for-fibro-inflammatory-diseases 2026-08-08T11:47:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mediar-therapeutics-enters-collaboration-with-ono-pharma-to-develop-novel-antibody-therapeutics-for-fibro-inflammatory-diseases 2026-08-08T11:47:44+00:00 hourly 0.9 https://trial.medpath.com/news/ribox-therapeutics-secures-fda-ind-clearance-for-rxim002-the-first-circular-rna-based-in-vivo-car-t-therapy 2026-08-08T08:47:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ribox-therapeutics-secures-fda-ind-clearance-for-rxim002-the-first-circular-rna-based-in-vivo-car-t-therapy 2026-08-08T08:47:34+00:00 hourly 0.9 https://trial.medpath.com/news/tufts-csdd-benchmarking-study-commissioned-by-syneos-health-links-clinical-sourcing-models-to-trial-performance-and-quality 2026-08-08T08:47:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tufts-csdd-benchmarking-study-commissioned-by-syneos-health-links-clinical-sourcing-models-to-trial-performance-and-quality 2026-08-08T08:47:27+00:00 hourly 0.9 https://trial.medpath.com/news/quidelortho-cuts-2026-guidance-as-china-ivd-pricing-headwinds-and-soft-respiratory-season-weigh-on-diagnostics-business 2026-08-08T07:47:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quidelortho-cuts-2026-guidance-as-china-ivd-pricing-headwinds-and-soft-respiratory-season-weigh-on-diagnostics-business 2026-08-08T07:47:56+00:00 hourly 0.9 https://trial.medpath.com/news/analysts-maintain-buy-ratings-on-vir-biotechnology-despite-widening-losses 2026-08-08T07:47:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/analysts-maintain-buy-ratings-on-vir-biotechnology-despite-widening-losses 2026-08-08T07:47:27+00:00 hourly 0.9 https://trial.medpath.com/news/machine-learning-identifies-hnrnpa2b1-rpe-and-taf15-as-potential-stress-granule-related-biomarkers-for-childhood-asthma 2026-08-08T05:48:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/machine-learning-identifies-hnrnpa2b1-rpe-and-taf15-as-potential-stress-granule-related-biomarkers-for-childhood-asthma 2026-08-08T05:48:10+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-endometrial-cancer-pipeline-gains-momentum-as-adcs-immunotherapy-and-targeted-combinations-reshape-treatment 2026-08-08T03:47:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advanced-endometrial-cancer-pipeline-gains-momentum-as-adcs-immunotherapy-and-targeted-combinations-reshape-treatment 2026-08-08T03:47:43+00:00 hourly 0.9 https://trial.medpath.com/news/david-sinclair-launches-lifespan-a-scientist-led-media-platform-as-first-human-epigenetic-reprogramming-trial-advances 2026-08-08T02:47:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/david-sinclair-launches-lifespan-a-scientist-led-media-platform-as-first-human-epigenetic-reprogramming-trial-advances 2026-08-08T02:47:43+00:00 hourly 0.9 https://trial.medpath.com/news/parkinson-s-drug-developers-shift-focus-to-neuroinflammation-as-alpha-synuclein-strategy-stalls 2026-08-07T23:47:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/parkinson-s-drug-developers-shift-focus-to-neuroinflammation-as-alpha-synuclein-strategy-stalls 2026-08-07T23:47:41+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-launches-legal-challenges-against-tirzepatide-generics 2026-08-07T23:47:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-launches-legal-challenges-against-tirzepatide-generics 2026-08-07T23:47:24+00:00 hourly 0.9 https://trial.medpath.com/news/navigating-clinical-trials-for-metastatic-bladder-cancer-a-guide-for-patients-and-clinicians 2026-08-07T22:52:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/navigating-clinical-trials-for-metastatic-bladder-cancer-a-guide-for-patients-and-clinicians 2026-08-07T22:52:08+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-considers-executive-order-targeting-vaccines-and-autism-despite-scientific-consensus 2026-08-07T22:52:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-considers-executive-order-targeting-vaccines-and-autism-despite-scientific-consensus 2026-08-07T22:52:01+00:00 hourly 0.9 https://trial.medpath.com/news/insurers-seek-14-premium-hike-for-small-business-health-plans-in-2027-kff-analysis-finds 2026-08-07T21:48:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insurers-seek-14-premium-hike-for-small-business-health-plans-in-2027-kff-analysis-finds 2026-08-07T21:48:51+00:00 hourly 0.9 https://trial.medpath.com/news/mmj-challenges-cms-over-medicare-program-funding-non-fda-approved-cannabinoid-products-while-demanding-fda-approval-pathway 2026-08-07T21:48:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mmj-challenges-cms-over-medicare-program-funding-non-fda-approved-cannabinoid-products-while-demanding-fda-approval-pathway 2026-08-07T21:48:46+00:00 hourly 0.9 https://trial.medpath.com/news/renew-biotechnologies-publishes-proof-of-concept-study-on-neuron-derived-cfdna-methylation-signatures-for-alzheimer-s-parkinson-s-and-als 2026-08-07T21:48:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/renew-biotechnologies-publishes-proof-of-concept-study-on-neuron-derived-cfdna-methylation-signatures-for-alzheimer-s-parkinson-s-and-als 2026-08-07T21:48:43+00:00 hourly 0.9 https://trial.medpath.com/news/egetis-emcitate-nda-for-mct8-deficiency-advances-toward-september-28-2026-fda-decision 2026-08-07T21:48:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/egetis-emcitate-nda-for-mct8-deficiency-advances-toward-september-28-2026-fda-decision 2026-08-07T21:48:14+00:00 hourly 0.9 https://trial.medpath.com/news/scalable-education-program-nearly-triples-skin-cancer-screening-rates-in-hct-survivors 2026-08-07T21:04:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scalable-education-program-nearly-triples-skin-cancer-screening-rates-in-hct-survivors 2026-08-07T21:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/patient-derived-breast-cancer-organoids-validate-i-spy2-biomarkers-and-predict-treatment-response 2026-08-07T21:03:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patient-derived-breast-cancer-organoids-validate-i-spy2-biomarkers-and-predict-treatment-response 2026-08-07T21:03:56+00:00 hourly 0.9 https://trial.medpath.com/news/physicians-call-for-urgent-reforms-to-sustain-the-future-of-neonatal-critical-care 2026-08-07T19:49:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/physicians-call-for-urgent-reforms-to-sustain-the-future-of-neonatal-critical-care 2026-08-07T19:49:28+00:00 hourly 0.9 https://trial.medpath.com/news/dr-reddy-s-laboratories-terminates-distribution-agreement-with-novartis-india-following-shareholding-change 2026-08-07T19:48:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dr-reddy-s-laboratories-terminates-distribution-agreement-with-novartis-india-following-shareholding-change 2026-08-07T19:48:46+00:00 hourly 0.9 https://trial.medpath.com/news/asia-pacific-navigates-the-aging-indication-gap-through-three-distinct-routes-but-therapeutic-development-lags-behind-service-delivery 2026-08-07T19:48:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asia-pacific-navigates-the-aging-indication-gap-through-three-distinct-routes-but-therapeutic-development-lags-behind-service-delivery 2026-08-07T19:48:05+00:00 hourly 0.9 https://trial.medpath.com/news/greenstone-biosciences-secures-nih-r61-grant-to-develop-ipsc-and-ai-driven-therapies-for-dmd-cardiac-fibrosis 2026-08-07T17:52:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/greenstone-biosciences-secures-nih-r61-grant-to-develop-ipsc-and-ai-driven-therapies-for-dmd-cardiac-fibrosis 2026-08-07T17:52:45+00:00 hourly 0.9 https://trial.medpath.com/news/revelation-biosciences-secures-fda-agreement-for-adaptive-phase-2-3-trial-of-gemini-in-acute-kidney-injury 2026-08-07T17:52:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revelation-biosciences-secures-fda-agreement-for-adaptive-phase-2-3-trial-of-gemini-in-acute-kidney-injury 2026-08-07T17:52:44+00:00 hourly 0.9 https://trial.medpath.com/news/micot-pharma-s-mt200605-hits-phase-ii-primary-endpoint-in-acute-ischemic-stroke-offering-first-in-class-multi-stage-neuroprotection 2026-08-07T17:51:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/micot-pharma-s-mt200605-hits-phase-ii-primary-endpoint-in-acute-ischemic-stroke-offering-first-in-class-multi-stage-neuroprotection 2026-08-07T17:51:42+00:00 hourly 0.9 https://trial.medpath.com/news/transcenta-sells-hangzhou-cdmo-plant-to-wuxi-biologics-for-rmb-190-million-then-licenses-hicb-platform-back-to-the-buyer 2026-08-07T17:51:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transcenta-sells-hangzhou-cdmo-plant-to-wuxi-biologics-for-rmb-190-million-then-licenses-hicb-platform-back-to-the-buyer 2026-08-07T17:51:18+00:00 hourly 0.9 https://trial.medpath.com/news/sucla2-usp10-gene-interaction-may-predict-breast-cancer-metastasis-risk-and-treatment-benefit 2026-08-07T17:51:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sucla2-usp10-gene-interaction-may-predict-breast-cancer-metastasis-risk-and-treatment-benefit 2026-08-07T17:51:08+00:00 hourly 0.9 https://trial.medpath.com/news/priovant-initiates-phase-3-beacon-trial-of-brepocitinib-in-cutaneous-sarcoidosis-following-breakthrough-therapy-designation 2026-08-07T17:49:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/priovant-initiates-phase-3-beacon-trial-of-brepocitinib-in-cutaneous-sarcoidosis-following-breakthrough-therapy-designation 2026-08-07T17:49:37+00:00 hourly 0.9 https://trial.medpath.com/news/post-translational-modifications-orchestrate-cd8-t-cell-exhaustion-from-signal-initiation-to-epigenetic-locking 2026-08-07T17:49:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/post-translational-modifications-orchestrate-cd8-t-cell-exhaustion-from-signal-initiation-to-epigenetic-locking 2026-08-07T17:49:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-emergency-use-authorization-for-drug-to-prevent-new-world-screwworm-in-multiple-species 2026-08-07T17:49:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-emergency-use-authorization-for-drug-to-prevent-new-world-screwworm-in-multiple-species 2026-08-07T17:49:10+00:00 hourly 0.9 https://trial.medpath.com/news/intrathecal-morphine-pump-transforms-stage-iv-bowel-cancer-patient-s-life-moving-her-off-palliative-care 2026-08-07T17:48:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intrathecal-morphine-pump-transforms-stage-iv-bowel-cancer-patient-s-life-moving-her-off-palliative-care 2026-08-07T17:48:04+00:00 hourly 0.9 https://trial.medpath.com/news/sunshine-biopharma-launches-generic-amoxicillin-in-canada-targeting-4-9-billion-global-market 2026-08-07T17:47:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sunshine-biopharma-launches-generic-amoxicillin-in-canada-targeting-4-9-billion-global-market 2026-08-07T17:47:26+00:00 hourly 0.9 https://trial.medpath.com/news/biomarin-acquires-alesta-therapeutics-and-its-hypophosphatasia-drug-ale1-in-275m-deal 2026-08-07T16:48:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarin-acquires-alesta-therapeutics-and-its-hypophosphatasia-drug-ale1-in-275m-deal 2026-08-07T16:48:10+00:00 hourly 0.9 https://trial.medpath.com/news/ligand-reports-32-royalty-revenue-growth-raises-eps-guidance-following-xoma-acquisition 2026-08-07T16:47:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ligand-reports-32-royalty-revenue-growth-raises-eps-guidance-following-xoma-acquisition 2026-08-07T16:47:31+00:00 hourly 0.9 https://trial.medpath.com/news/consistent-diabetes-medication-adherence-linked-to-fewer-heart-attacks-and-strokes-decade-long-danish-study-finds 2026-08-07T14:49:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/consistent-diabetes-medication-adherence-linked-to-fewer-heart-attacks-and-strokes-decade-long-danish-study-finds 2026-08-07T14:49:24+00:00 hourly 0.9 https://trial.medpath.com/news/google-deepmind-veterans-launch-discovery-loop-to-automate-scientific-discovery-with-ai 2026-08-07T14:48:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/google-deepmind-veterans-launch-discovery-loop-to-automate-scientific-discovery-with-ai 2026-08-07T14:48:49+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-ceo-reshma-kewalramani-leads-crispr-revolution-as-pharma-s-top-women-executives-reshape-the-industry 2026-08-07T14:48:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertex-ceo-reshma-kewalramani-leads-crispr-revolution-as-pharma-s-top-women-executives-reshape-the-industry 2026-08-07T14:48:28+00:00 hourly 0.9 https://trial.medpath.com/news/neurocrine-biosciences-launches-phase-i-trial-of-glp-1-gip-glucagon-triple-agonist-nbip-1968-for-obesity 2026-08-07T14:48:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurocrine-biosciences-launches-phase-i-trial-of-glp-1-gip-glucagon-triple-agonist-nbip-1968-for-obesity 2026-08-07T14:48:25+00:00 hourly 0.9 https://trial.medpath.com/news/new-mexico-court-orders-meta-to-pay-567-million-mandates-sweeping-teen-safety-overhaul-on-facebook-and-instagram 2026-08-07T14:48:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-mexico-court-orders-meta-to-pay-567-million-mandates-sweeping-teen-safety-overhaul-on-facebook-and-instagram 2026-08-07T14:48:21+00:00 hourly 0.9 https://trial.medpath.com/news/zebrafish-study-reveals-bisphosphonates-may-block-pathological-spine-mineralization-opening-first-pharmacological-path-for-disc-degeneration 2026-08-07T13:47:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zebrafish-study-reveals-bisphosphonates-may-block-pathological-spine-mineralization-opening-first-pharmacological-path-for-disc-degeneration 2026-08-07T13:47:29+00:00 hourly 0.9 https://trial.medpath.com/news/health-catalyst-closes-vitalware-divestiture-and-retires-160-million-in-debt-to-refocus-on-healthcare-intelligence 2026-08-07T13:47:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-catalyst-closes-vitalware-divestiture-and-retires-160-million-in-debt-to-refocus-on-healthcare-intelligence 2026-08-07T13:47:25+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-antidepressant-users-may-need-slower-hyperbolic-tapers-as-withdrawal-concerns-grow 2026-08-07T12:48:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-antidepressant-users-may-need-slower-hyperbolic-tapers-as-withdrawal-concerns-grow 2026-08-07T12:48:13+00:00 hourly 0.9 https://trial.medpath.com/news/lz901-recombinant-herpes-zoster-vaccine-demonstrates-91-6-efficacy-in-phase-iii-trial-published-in-nature-communications 2026-08-07T11:47:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lz901-recombinant-herpes-zoster-vaccine-demonstrates-91-6-efficacy-in-phase-iii-trial-published-in-nature-communications 2026-08-07T11:47:32+00:00 hourly 0.9 https://trial.medpath.com/news/anthropic-reduces-claude-fable-5-biology-fallbacks-by-85-expands-access-for-clinicians-while-researchers-remain-locked-out 2026-08-07T10:49:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anthropic-reduces-claude-fable-5-biology-fallbacks-by-85-expands-access-for-clinicians-while-researchers-remain-locked-out 2026-08-07T10:49:28+00:00 hourly 0.9 https://trial.medpath.com/news/riyadh-global-medical-biotechnology-summit-2026-to-convene-world-s-biotech-leaders-in-september 2026-08-07T10:48:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/riyadh-global-medical-biotechnology-summit-2026-to-convene-world-s-biotech-leaders-in-september 2026-08-07T10:48:36+00:00 hourly 0.9 https://trial.medpath.com/news/dispatch-bio-doses-first-patient-in-phase-1-trial-of-disp-10-a-novel-synthetic-antigen-car-t-immunotherapy-for-advanced-gi-cancers-secures-fda-fast-track-designation 2026-08-07T06:48:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dispatch-bio-doses-first-patient-in-phase-1-trial-of-disp-10-a-novel-synthetic-antigen-car-t-immunotherapy-for-advanced-gi-cancers-secures-fda-fast-track-designation 2026-08-07T06:48:19+00:00 hourly 0.9 https://trial.medpath.com/news/kardium-s-globe-pulsed-field-system-secures-health-canada-approval-for-atrial-fibrillation-treatment 2026-08-07T05:48:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kardium-s-globe-pulsed-field-system-secures-health-canada-approval-for-atrial-fibrillation-treatment 2026-08-07T05:48:02+00:00 hourly 0.9 https://trial.medpath.com/news/starling-oncology-reports-q2-2026-revenue-surge-raises-full-year-guidance-as-adjusted-ebitda-turns-positive 2026-08-07T04:52:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/starling-oncology-reports-q2-2026-revenue-surge-raises-full-year-guidance-as-adjusted-ebitda-turns-positive 2026-08-07T04:52:58+00:00 hourly 0.9 https://trial.medpath.com/news/exobiosphere-secures-eur1m-non-dilutive-funding-to-scale-space-based-drug-discovery-platform 2026-08-07T04:52:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exobiosphere-secures-eur1m-non-dilutive-funding-to-scale-space-based-drug-discovery-platform 2026-08-07T04:52:56+00:00 hourly 0.9 https://trial.medpath.com/news/ai-and-genetics-converge-to-identify-novel-wnk2-inhibitor-as-potential-disease-modifying-osteoarthritis-therapy 2026-08-07T04:52:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-and-genetics-converge-to-identify-novel-wnk2-inhibitor-as-potential-disease-modifying-osteoarthritis-therapy 2026-08-07T04:52:55+00:00 hourly 0.9 https://trial.medpath.com/news/energenesis-biomedical-and-taiwan-tanabe-seiyaku-enter-joint-development-agreement-for-diabetic-foot-ulcer-candidate-energi-f703dfu 2026-08-07T04:52:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/energenesis-biomedical-and-taiwan-tanabe-seiyaku-enter-joint-development-agreement-for-diabetic-foot-ulcer-candidate-energi-f703dfu 2026-08-07T04:52:15+00:00 hourly 0.9 https://trial.medpath.com/news/steris-announces-600-million-center-of-excellence-in-north-carolina-for-infection-prevention-chemistries 2026-08-07T04:52:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/steris-announces-600-million-center-of-excellence-in-north-carolina-for-infection-prevention-chemistries 2026-08-07T04:52:14+00:00 hourly 0.9 https://trial.medpath.com/news/sydney-towle-content-creator-who-documented-cholangiocarcinoma-journey-dies-at-26 2026-08-07T04:52:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sydney-towle-content-creator-who-documented-cholangiocarcinoma-journey-dies-at-26 2026-08-07T04:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/nearly-10-million-americans-with-untreated-high-blood-pressure-could-benefit-from-medication-under-new-guidelines 2026-08-07T03:53:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nearly-10-million-americans-with-untreated-high-blood-pressure-could-benefit-from-medication-under-new-guidelines 2026-08-07T03:53:09+00:00 hourly 0.9 https://trial.medpath.com/news/analysts-maintain-buy-ratings-on-fresenius-se-co-kgaa-amid-positive-insider-sentiment 2026-08-07T02:47:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/analysts-maintain-buy-ratings-on-fresenius-se-co-kgaa-amid-positive-insider-sentiment 2026-08-07T02:47:27+00:00 hourly 0.9 https://trial.medpath.com/news/high-dose-vitamin-d3-fails-to-improve-outcomes-in-metastatic-colorectal-cancer-phase-3-trial-finds 2026-08-07T01:48:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/high-dose-vitamin-d3-fails-to-improve-outcomes-in-metastatic-colorectal-cancer-phase-3-trial-finds 2026-08-07T01:48:03+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-gene-editing-creates-hypoallergenic-beagles-in-first-of-its-kind-study 2026-08-07T01:47:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-gene-editing-creates-hypoallergenic-beagles-in-first-of-its-kind-study 2026-08-07T01:47:55+00:00 hourly 0.9 https://trial.medpath.com/news/natera-reports-record-signatera-volumes-in-q2-2026-raises-guidance-on-mrd-market-momentum 2026-08-07T00:47:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/natera-reports-record-signatera-volumes-in-q2-2026-raises-guidance-on-mrd-market-momentum 2026-08-07T00:47:45+00:00 hourly 0.9 https://trial.medpath.com/news/uab-translational-and-molecular-sciences-t32-training-program-renewed-by-nih-for-five-years-with-expanded-trainee-slots 2026-08-06T23:48:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uab-translational-and-molecular-sciences-t32-training-program-renewed-by-nih-for-five-years-with-expanded-trainee-slots 2026-08-06T23:48:05+00:00 hourly 0.9 https://trial.medpath.com/news/florida-invests-2-million-to-expand-fiu-s-functional-precision-oncology-program-for-treatment-resistant-cancers 2026-08-06T23:47:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/florida-invests-2-million-to-expand-fiu-s-functional-precision-oncology-program-for-treatment-resistant-cancers 2026-08-06T23:47:59+00:00 hourly 0.9 https://trial.medpath.com/news/recode-therapeutics-secures-cystic-fibrosis-foundation-funding-launches-gene-editing-collaboration-and-names-heather-clark-as-ceo 2026-08-06T22:54:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recode-therapeutics-secures-cystic-fibrosis-foundation-funding-launches-gene-editing-collaboration-and-names-heather-clark-as-ceo 2026-08-06T22:54:02+00:00 hourly 0.9 https://trial.medpath.com/news/v-foundation-awards-1-million-grant-to-cu-anschutz-for-infant-all-research-targeting-menin-inhibition 2026-08-06T22:53:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/v-foundation-awards-1-million-grant-to-cu-anschutz-for-infant-all-research-targeting-menin-inhibition 2026-08-06T22:53:43+00:00 hourly 0.9 https://trial.medpath.com/news/mainehealth-lincoln-hospital-transitions-labor-and-delivery-to-regional-model-preserving-prenatal-and-gynecologic-care-locally 2026-08-06T22:53:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mainehealth-lincoln-hospital-transitions-labor-and-delivery-to-regional-model-preserving-prenatal-and-gynecologic-care-locally 2026-08-06T22:53:27+00:00 hourly 0.9 https://trial.medpath.com/news/ai-model-trained-on-dna-creates-16-novel-viruses-raising-both-therapeutic-promise-and-biosecurity-alarms 2026-08-06T22:53:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-model-trained-on-dna-creates-16-novel-viruses-raising-both-therapeutic-promise-and-biosecurity-alarms 2026-08-06T22:53:22+00:00 hourly 0.9 https://trial.medpath.com/news/nafdac-issues-public-alert-over-counterfeit-forxiga-dapagliflozin-circulating-in-nigeria 2026-08-06T22:52:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nafdac-issues-public-alert-over-counterfeit-forxiga-dapagliflozin-circulating-in-nigeria 2026-08-06T22:52:55+00:00 hourly 0.9 https://trial.medpath.com/news/mercy-earns-klas-arch-collaborative-level-6-pinnacle-recognition-for-physician-ehr-experience 2026-08-06T21:48:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mercy-earns-klas-arch-collaborative-level-6-pinnacle-recognition-for-physician-ehr-experience 2026-08-06T21:48:02+00:00 hourly 0.9 https://trial.medpath.com/news/aclaris-therapeutics-receives-fda-fast-track-designation-for-modzatinib-in-moderate-to-severe-lichen-planus 2026-08-06T21:47:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aclaris-therapeutics-receives-fda-fast-track-designation-for-modzatinib-in-moderate-to-severe-lichen-planus 2026-08-06T21:47:59+00:00 hourly 0.9 https://trial.medpath.com/news/end-of-life-doulas-non-medical-companions-bridging-autonomy-and-care-in-cancer-patients-final-days 2026-08-06T21:47:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/end-of-life-doulas-non-medical-companions-bridging-autonomy-and-care-in-cancer-patients-final-days 2026-08-06T21:47:32+00:00 hourly 0.9 https://trial.medpath.com/news/ucsf-study-reveals-fat-tissue-fibrosis-drives-hidden-diabetes-risk-in-non-obese-hiv-patients 2026-08-06T21:47:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucsf-study-reveals-fat-tissue-fibrosis-drives-hidden-diabetes-risk-in-non-obese-hiv-patients 2026-08-06T21:47:23+00:00 hourly 0.9 https://trial.medpath.com/news/first-complete-diploid-human-genome-ushers-in-new-era-of-personalized-medicine 2026-08-06T20:50:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-complete-diploid-human-genome-ushers-in-new-era-of-personalized-medicine 2026-08-06T20:50:03+00:00 hourly 0.9 https://trial.medpath.com/news/scholar-rock-advances-apitegromab-toward-september-30-pdufa-date-as-first-muscle-targeted-therapy-for-sma 2026-08-06T20:49:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scholar-rock-advances-apitegromab-toward-september-30-pdufa-date-as-first-muscle-targeted-therapy-for-sma 2026-08-06T20:49:51+00:00 hourly 0.9 https://trial.medpath.com/news/doj-seeks-permanent-injunction-against-nevada-s-steiner-biotechnology-over-adulterated-dental-devices 2026-08-06T20:49:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/doj-seeks-permanent-injunction-against-nevada-s-steiner-biotechnology-over-adulterated-dental-devices 2026-08-06T20:49:29+00:00 hourly 0.9 https://trial.medpath.com/news/bone-resorption-and-constipation-predict-higher-tenapanor-dose-requirements-in-dialysis-patients-with-hyperphosphatemia 2026-08-06T20:48:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bone-resorption-and-constipation-predict-higher-tenapanor-dose-requirements-in-dialysis-patients-with-hyperphosphatemia 2026-08-06T20:48:57+00:00 hourly 0.9 https://trial.medpath.com/news/il-6-receptor-blockers-show-promise-for-preventing-relapses-in-rare-autoimmune-neurological-disorder-mogad 2026-08-06T20:48:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/il-6-receptor-blockers-show-promise-for-preventing-relapses-in-rare-autoimmune-neurological-disorder-mogad 2026-08-06T20:48:12+00:00 hourly 0.9 https://trial.medpath.com/news/psychiatrists-testify-lindsay-clancy-showed-no-signs-of-psychosis-before-children-s-deaths 2026-08-06T18:48:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psychiatrists-testify-lindsay-clancy-showed-no-signs-of-psychosis-before-children-s-deaths 2026-08-06T18:48:22+00:00 hourly 0.9 https://trial.medpath.com/news/creative-medical-receives-u-s-patent-allowance-for-exosome-based-type-1-diabetes-immunotherapy 2026-08-06T18:47:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/creative-medical-receives-u-s-patent-allowance-for-exosome-based-type-1-diabetes-immunotherapy 2026-08-06T18:47:38+00:00 hourly 0.9 https://trial.medpath.com/news/sk-biopharm-settles-us-patent-suit-over-xcopri-reinforcing-long-term-market-exclusivity 2026-08-06T17:49:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sk-biopharm-settles-us-patent-suit-over-xcopri-reinforcing-long-term-market-exclusivity 2026-08-06T17:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/ensysce-biosciences-acquires-cy-biopharma-secures-up-to-77-million-to-advance-orphan-designated-crps-therapy 2026-08-06T17:48:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ensysce-biosciences-acquires-cy-biopharma-secures-up-to-77-million-to-advance-orphan-designated-crps-therapy 2026-08-06T17:48:09+00:00 hourly 0.9 https://trial.medpath.com/news/md-anderson-study-reveals-macrophage-dysfunction-not-absence-drives-aggressive-skin-cancer-in-immunosuppressed-patients 2026-08-06T17:47:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/md-anderson-study-reveals-macrophage-dysfunction-not-absence-drives-aggressive-skin-cancer-in-immunosuppressed-patients 2026-08-06T17:47:23+00:00 hourly 0.9 https://trial.medpath.com/news/tarsus-to-acquire-alkeus-pharmaceuticals-for-up-to-800-million-securing-late-stage-stargardt-disease-drug-gildeuretinol 2026-08-06T16:51:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tarsus-to-acquire-alkeus-pharmaceuticals-for-up-to-800-million-securing-late-stage-stargardt-disease-drug-gildeuretinol 2026-08-06T16:51:40+00:00 hourly 0.9 https://trial.medpath.com/news/northwest-biotherapeutics-signs-mou-with-spimaco-to-bring-dcvax-l-personalized-immunotherapy-for-glioblastoma-to-saudi-arabia 2026-08-06T16:51:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/northwest-biotherapeutics-signs-mou-with-spimaco-to-bring-dcvax-l-personalized-immunotherapy-for-glioblastoma-to-saudi-arabia 2026-08-06T16:51:31+00:00 hourly 0.9 https://trial.medpath.com/news/mathematical-biomarkers-predict-prostate-cancer-outcomes-in-adaptive-therapy 2026-08-06T16:51:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mathematical-biomarkers-predict-prostate-cancer-outcomes-in-adaptive-therapy 2026-08-06T16:51:11+00:00 hourly 0.9 https://trial.medpath.com/news/risk-adapted-frameworks-reshape-pediatric-neuroblastoma-care-new-review-shows 2026-08-06T16:47:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/risk-adapted-frameworks-reshape-pediatric-neuroblastoma-care-new-review-shows 2026-08-06T16:47:33+00:00 hourly 0.9 https://trial.medpath.com/news/sonablate-and-eleven-ventures-forge-200-million-strategic-alliance-to-advance-ai-powered-therapeutic-ultrasound-globally 2026-08-06T15:48:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sonablate-and-eleven-ventures-forge-200-million-strategic-alliance-to-advance-ai-powered-therapeutic-ultrasound-globally 2026-08-06T15:48:23+00:00 hourly 0.9 https://trial.medpath.com/news/lifemine-therapeutics-raises-263m-to-advance-novel-calcineurin-inhibitor-life-001-for-organ-transplant-rejection 2026-08-06T15:48:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lifemine-therapeutics-raises-263m-to-advance-novel-calcineurin-inhibitor-life-001-for-organ-transplant-rejection 2026-08-06T15:48:13+00:00 hourly 0.9 https://trial.medpath.com/news/pacira-s-gene-therapy-pcrx-201-shows-durable-two-year-benefit-in-knee-osteoarthritis-phase-1-data-published-in-annals-of-the-rheumatic-diseases 2026-08-06T14:47:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pacira-s-gene-therapy-pcrx-201-shows-durable-two-year-benefit-in-knee-osteoarthritis-phase-1-data-published-in-annals-of-the-rheumatic-diseases 2026-08-06T14:47:27+00:00 hourly 0.9 https://trial.medpath.com/news/tenax-therapeutics-phase-3-level-trial-of-tnx-103-fails-to-meet-primary-endpoint-in-ph-hfpef 2026-08-06T14:47:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tenax-therapeutics-phase-3-level-trial-of-tnx-103-fails-to-meet-primary-endpoint-in-ph-hfpef 2026-08-06T14:47:23+00:00 hourly 0.9 https://trial.medpath.com/news/generate-biomedicines-gb-0895-shows-durable-6-month-biomarker-suppression-in-phase-1-supporting-6-month-sc-dosing-in-severe-asthma 2026-08-06T13:49:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/generate-biomedicines-gb-0895-shows-durable-6-month-biomarker-suppression-in-phase-1-supporting-6-month-sc-dosing-in-severe-asthma 2026-08-06T13:49:01+00:00 hourly 0.9 https://trial.medpath.com/news/medicare-part-d-protected-classes-see-58-initial-rejection-rate-despite-coverage-protections 2026-08-06T13:48:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicare-part-d-protected-classes-see-58-initial-rejection-rate-despite-coverage-protections 2026-08-06T13:48:53+00:00 hourly 0.9 https://trial.medpath.com/news/carvolix-secures-eur30m-structured-debt-financing-from-claret-capital-to-accelerate-ai-driven-cardiovascular-robotics 2026-08-06T12:47:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carvolix-secures-eur30m-structured-debt-financing-from-claret-capital-to-accelerate-ai-driven-cardiovascular-robotics 2026-08-06T12:47:47+00:00 hourly 0.9 https://trial.medpath.com/news/windrose-health-investors-recapitalizes-verified-clinical-trials-appoints-howard-miller-as-ceo-to-accelerate-growth 2026-08-06T12:01:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/windrose-health-investors-recapitalizes-verified-clinical-trials-appoints-howard-miller-as-ceo-to-accelerate-growth 2026-08-06T12:01:30+00:00 hourly 0.9 https://trial.medpath.com/news/actimed-therapeutics-reacquires-global-rights-to-s-oxprenolol-after-faraday-pharmaceuticals-collapse 2026-08-06T12:01:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actimed-therapeutics-reacquires-global-rights-to-s-oxprenolol-after-faraday-pharmaceuticals-collapse 2026-08-06T12:01:04+00:00 hourly 0.9 https://trial.medpath.com/news/kodiak-sciences-completes-enrollment-in-first-pivotal-cohort-of-phase-3-peak-trial-for-ksi-101-in-macular-edema-secondary-to-inflammation 2026-08-06T12:01:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kodiak-sciences-completes-enrollment-in-first-pivotal-cohort-of-phase-3-peak-trial-for-ksi-101-in-macular-edema-secondary-to-inflammation 2026-08-06T12:01:03+00:00 hourly 0.9 https://trial.medpath.com/news/vedanta-biosciences-secures-60-million-to-advance-phase-3-microbiome-therapy-ve303-for-recurrent-c-difficile-infection 2026-08-06T12:00:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vedanta-biosciences-secures-60-million-to-advance-phase-3-microbiome-therapy-ve303-for-recurrent-c-difficile-infection 2026-08-06T12:00:40+00:00 hourly 0.9 https://trial.medpath.com/news/neutrophil-derived-il-4-drives-spinal-cord-regeneration-in-zebrafish-study-finds 2026-08-06T12:00:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neutrophil-derived-il-4-drives-spinal-cord-regeneration-in-zebrafish-study-finds 2026-08-06T12:00:39+00:00 hourly 0.9 https://trial.medpath.com/news/xencor-reports-q2-2026-results-and-advances-xmab819-xmab541-and-xmab942-clinical-programs 2026-08-06T11:59:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xencor-reports-q2-2026-results-and-advances-xmab819-xmab541-and-xmab942-clinical-programs 2026-08-06T11:59:09+00:00 hourly 0.9 https://trial.medpath.com/news/evotec-and-odyssey-therapeutics-enter-ai-enabled-r-d-collaboration-to-discover-novel-therapies-for-autoimmune-and-inflammatory-diseases 2026-08-06T10:47:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evotec-and-odyssey-therapeutics-enter-ai-enabled-r-d-collaboration-to-discover-novel-therapies-for-autoimmune-and-inflammatory-diseases 2026-08-06T10:47:52+00:00 hourly 0.9 https://trial.medpath.com/news/msf-launches-dengue-response-project-in-tegucigalpa-as-honduras-faces-escalating-outbreak 2026-08-06T10:47:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/msf-launches-dengue-response-project-in-tegucigalpa-as-honduras-faces-escalating-outbreak 2026-08-06T10:47:51+00:00 hourly 0.9 https://trial.medpath.com/news/senhwa-s-cx-5461-reaches-immuno-oncology-milestone-as-first-multicenter-combination-trial-with-pd-1-inhibitor-receives-tfda-clearance 2026-08-06T10:47:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senhwa-s-cx-5461-reaches-immuno-oncology-milestone-as-first-multicenter-combination-trial-with-pd-1-inhibitor-receives-tfda-clearance 2026-08-06T10:47:47+00:00 hourly 0.9 https://trial.medpath.com/news/clarivate-scales-agentic-ai-across-cortellis-portfolio-to-accelerate-drug-development-decisions 2026-08-06T09:47:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clarivate-scales-agentic-ai-across-cortellis-portfolio-to-accelerate-drug-development-decisions 2026-08-06T09:47:25+00:00 hourly 0.9 https://trial.medpath.com/news/molecular-editing-unlocks-new-chemical-space-in-pyridine-based-drug-discovery 2026-08-06T05:49:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/molecular-editing-unlocks-new-chemical-space-in-pyridine-based-drug-discovery 2026-08-06T05:49:46+00:00 hourly 0.9 https://trial.medpath.com/news/chewing-gum-made-from-lablab-beans-reduces-hpv-by-93-and-nearly-eradicates-cancer-linked-oral-bacteria 2026-08-06T02:49:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chewing-gum-made-from-lablab-beans-reduces-hpv-by-93-and-nearly-eradicates-cancer-linked-oral-bacteria 2026-08-06T02:49:33+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-moves-to-shut-kentucky-organ-procurement-organization-citing-persistent-safety-failures 2026-08-06T02:49:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-moves-to-shut-kentucky-organ-procurement-organization-citing-persistent-safety-failures 2026-08-06T02:49:08+00:00 hourly 0.9 https://trial.medpath.com/news/insilico-medicine-nominates-ai-designed-ism9077-as-first-in-class-preclinical-candidate-for-ocular-and-inflammatory-diseases 2026-08-06T01:50:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insilico-medicine-nominates-ai-designed-ism9077-as-first-in-class-preclinical-candidate-for-ocular-and-inflammatory-diseases 2026-08-06T01:50:37+00:00 hourly 0.9 https://trial.medpath.com/news/cellfiber-and-tidewave-bio-partner-to-evaluate-3d-manufacturing-for-off-the-shelf-solid-tumor-immunotherapy 2026-08-06T01:50:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellfiber-and-tidewave-bio-partner-to-evaluate-3d-manufacturing-for-off-the-shelf-solid-tumor-immunotherapy 2026-08-06T01:50:33+00:00 hourly 0.9 https://trial.medpath.com/news/canada-to-build-267-million-medical-countermeasures-lab-in-winnipeg-to-bolster-pandemic-preparedness 2026-08-06T01:50:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canada-to-build-267-million-medical-countermeasures-lab-in-winnipeg-to-bolster-pandemic-preparedness 2026-08-06T01:50:06+00:00 hourly 0.9 https://trial.medpath.com/news/massive-genomic-study-identifies-fnip1-skinny-gene-mutation-that-mimics-glp-1-drug-effects 2026-08-05T23:50:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/massive-genomic-study-identifies-fnip1-skinny-gene-mutation-that-mimics-glp-1-drug-effects 2026-08-05T23:50:54+00:00 hourly 0.9 https://trial.medpath.com/news/imdelltra-bite-therapy-shows-game-changer-results-in-small-cell-lung-cancer-patients 2026-08-05T23:50:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imdelltra-bite-therapy-shows-game-changer-results-in-small-cell-lung-cancer-patients 2026-08-05T23:50:22+00:00 hourly 0.9 https://trial.medpath.com/news/phase-1-trial-shows-fridge-free-tetanus-diphtheria-vaccine-matches-standard-boosters-in-safety-and-immunogenicity 2026-08-05T23:50:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-1-trial-shows-fridge-free-tetanus-diphtheria-vaccine-matches-standard-boosters-in-safety-and-immunogenicity 2026-08-05T23:50:19+00:00 hourly 0.9 https://trial.medpath.com/news/us-australia-collaboration-aims-to-accelerate-early-stage-clinical-trials-and-strengthen-american-biotech-competitiveness 2026-08-05T23:50:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-australia-collaboration-aims-to-accelerate-early-stage-clinical-trials-and-strengthen-american-biotech-competitiveness 2026-08-05T23:50:14+00:00 hourly 0.9 https://trial.medpath.com/news/evonik-breaks-ground-on-eur80-million-biotech-expansion-at-slovakian-fermas-site 2026-08-05T23:49:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evonik-breaks-ground-on-eur80-million-biotech-expansion-at-slovakian-fermas-site 2026-08-05T23:49:52+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-weight-loss-jabs-linked-to-rising-gallstone-disease-and-gallbladder-surgery-as-unapproved-retatrutide-fuels-black-market 2026-08-05T23:49:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-weight-loss-jabs-linked-to-rising-gallstone-disease-and-gallbladder-surgery-as-unapproved-retatrutide-fuels-black-market 2026-08-05T23:49:48+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-to-acquire-apogee-therapeutics-for-135-11-per-share-in-landmark-immunology-deal 2026-08-05T22:53:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-to-acquire-apogee-therapeutics-for-135-11-per-share-in-landmark-immunology-deal 2026-08-05T22:53:29+00:00 hourly 0.9 https://trial.medpath.com/news/cu-anschutz-rheumatologists-expand-access-to-care-through-econsults-and-off-campus-clinics 2026-08-05T21:50:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cu-anschutz-rheumatologists-expand-access-to-care-through-econsults-and-off-campus-clinics 2026-08-05T21:50:53+00:00 hourly 0.9 https://trial.medpath.com/news/uk-launches-mrc-centre-of-research-excellence-to-pioneer-mitochondrial-genome-therapeutics 2026-08-05T21:50:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-launches-mrc-centre-of-research-excellence-to-pioneer-mitochondrial-genome-therapeutics 2026-08-05T21:50:24+00:00 hourly 0.9 https://trial.medpath.com/news/single-cell-and-spatial-omics-take-center-stage-at-2026-2027-international-conferences 2026-08-05T21:49:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-cell-and-spatial-omics-take-center-stage-at-2026-2027-international-conferences 2026-08-05T21:49:01+00:00 hourly 0.9 https://trial.medpath.com/news/dronabinol-eliminates-ptsd-nightmares-in-over-one-third-of-patients-in-phase-iii-trial 2026-08-05T20:51:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dronabinol-eliminates-ptsd-nightmares-in-over-one-third-of-patients-in-phase-iii-trial 2026-08-05T20:51:11+00:00 hourly 0.9 https://trial.medpath.com/news/dick-vitale-reports-immunotherapy-effectively-wiping-out-cancer-in-fifth-diagnosis 2026-08-05T20:49:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dick-vitale-reports-immunotherapy-effectively-wiping-out-cancer-in-fifth-diagnosis 2026-08-05T20:49:12+00:00 hourly 0.9 https://trial.medpath.com/news/nextel-medical-to-acquire-xycota-biosciences-gaining-exosome-delivered-neuro-restoration-platform-with-pending-fda-orphan-drug-designation 2026-08-05T19:52:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nextel-medical-to-acquire-xycota-biosciences-gaining-exosome-delivered-neuro-restoration-platform-with-pending-fda-orphan-drug-designation 2026-08-05T19:52:14+00:00 hourly 0.9 https://trial.medpath.com/news/marvel-biosciences-mb-204-reverses-behavioural-and-cognitive-deficits-in-fragile-x-mouse-model-marking-third-preclinical-asd-success 2026-08-05T19:51:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marvel-biosciences-mb-204-reverses-behavioural-and-cognitive-deficits-in-fragile-x-mouse-model-marking-third-preclinical-asd-success 2026-08-05T19:51:45+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-pharmaceuticals-advances-first-ai-discovered-neuroscience-target-with-genentech-lowers-cash-burn-guidance 2026-08-05T19:51:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recursion-pharmaceuticals-advances-first-ai-discovered-neuroscience-target-with-genentech-lowers-cash-burn-guidance 2026-08-05T19:51:19+00:00 hourly 0.9 https://trial.medpath.com/news/fecal-microbiome-transplant-shows-promise-as-novel-treatment-for-peanut-allergy-in-first-in-human-trial 2026-08-05T18:50:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fecal-microbiome-transplant-shows-promise-as-novel-treatment-for-peanut-allergy-in-first-in-human-trial 2026-08-05T18:50:13+00:00 hourly 0.9 https://trial.medpath.com/news/human-cancer-model-initiative-publishes-665-next-generation-patient-derived-organoid-models-spanning-25-cancer-types 2026-08-05T18:50:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/human-cancer-model-initiative-publishes-665-next-generation-patient-derived-organoid-models-spanning-25-cancer-types 2026-08-05T18:50:12+00:00 hourly 0.9 https://trial.medpath.com/news/uk-biobank-study-links-ckm-syndrome-stages-to-stepwise-cancer-risk-via-distinct-immune-metabolic-pathways 2026-08-05T18:50:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-biobank-study-links-ckm-syndrome-stages-to-stepwise-cancer-risk-via-distinct-immune-metabolic-pathways 2026-08-05T18:50:10+00:00 hourly 0.9 https://trial.medpath.com/news/nice-breast-cancer-referral-criteria-miss-95-of-at-risk-women-under-50-study-finds 2026-08-05T17:49:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-breast-cancer-referral-criteria-miss-95-of-at-risk-women-under-50-study-finds 2026-08-05T17:49:56+00:00 hourly 0.9 https://trial.medpath.com/news/next-generation-3d-cancer-models-reveal-clinically-relevant-gene-dependencies-missed-by-traditional-cell-lines 2026-08-05T17:49:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/next-generation-3d-cancer-models-reveal-clinically-relevant-gene-dependencies-missed-by-traditional-cell-lines 2026-08-05T17:49:51+00:00 hourly 0.9 https://trial.medpath.com/news/lemaitre-vascular-reports-record-q2-2026-results-driven-by-artegraft-global-expansion 2026-08-05T17:49:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lemaitre-vascular-reports-record-q2-2026-results-driven-by-artegraft-global-expansion 2026-08-05T17:49:50+00:00 hourly 0.9 https://trial.medpath.com/news/payam-saadai-appointed-chief-of-pediatric-general-thoracic-and-fetal-surgery-at-uc-davis-health 2026-08-05T17:49:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/payam-saadai-appointed-chief-of-pediatric-general-thoracic-and-fetal-surgery-at-uc-davis-health 2026-08-05T17:49:45+00:00 hourly 0.9 https://trial.medpath.com/news/fc-optimized-gitr-antibody-boosts-cd4-t-cell-dendritic-cell-teamwork-against-tumors 2026-08-05T17:49:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fc-optimized-gitr-antibody-boosts-cd4-t-cell-dendritic-cell-teamwork-against-tumors 2026-08-05T17:49:37+00:00 hourly 0.9 https://trial.medpath.com/news/nsf-awards-utoledo-nearly-1m-for-high-resolution-maldi-ms-to-advance-drug-development-and-disease-research 2026-08-05T17:49:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nsf-awards-utoledo-nearly-1m-for-high-resolution-maldi-ms-to-advance-drug-development-and-disease-research 2026-08-05T17:49:11+00:00 hourly 0.9 https://trial.medpath.com/news/charles-river-laboratories-raises-2026-profit-forecast-on-strengthening-biotech-demand 2026-08-05T16:55:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/charles-river-laboratories-raises-2026-profit-forecast-on-strengthening-biotech-demand 2026-08-05T16:55:28+00:00 hourly 0.9 https://trial.medpath.com/news/aacr-launches-first-of-its-kind-phase-ii-trial-testing-organ-preservation-in-gastroesophageal-cancer 2026-08-05T16:54:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aacr-launches-first-of-its-kind-phase-ii-trial-testing-organ-preservation-in-gastroesophageal-cancer 2026-08-05T16:54:46+00:00 hourly 0.9 https://trial.medpath.com/news/expedition-therapeutics-raises-115m-series-b-to-advance-first-global-phase-2-trial-of-dpp1-inhibitor-in-copd 2026-08-05T16:52:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/expedition-therapeutics-raises-115m-series-b-to-advance-first-global-phase-2-trial-of-dpp1-inhibitor-in-copd 2026-08-05T16:52:42+00:00 hourly 0.9 https://trial.medpath.com/news/light-activated-nanorobots-enable-targeted-phototherapy-for-breast-cancer 2026-08-05T16:52:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/light-activated-nanorobots-enable-targeted-phototherapy-for-breast-cancer 2026-08-05T16:52:01+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-affirms-non-infringement-ruling-clearing-path-for-aveva-s-generic-ztlido-launch 2026-08-05T16:51:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-affirms-non-infringement-ruling-clearing-path-for-aveva-s-generic-ztlido-launch 2026-08-05T16:51:44+00:00 hourly 0.9 https://trial.medpath.com/news/when-diagnosis-waits-lung-cancer-pet-access-and-global-oncology 2026-08-05T16:51:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/when-diagnosis-waits-lung-cancer-pet-access-and-global-oncology 2026-08-05T16:51:17+00:00 hourly 0.9 https://trial.medpath.com/news/mindfulness-based-therapy-for-opioid-misuse-delivers-12-in-savings-for-every-1-spent-uc-san-diego-analysis-finds 2026-08-05T16:51:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mindfulness-based-therapy-for-opioid-misuse-delivers-12-in-savings-for-every-1-spent-uc-san-diego-analysis-finds 2026-08-05T16:51:07+00:00 hourly 0.9 https://trial.medpath.com/news/fda-weighs-approval-of-moderna-s-mrna-flu-vaccine-mflusiva-amid-political-scrutiny 2026-08-05T16:50:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-weighs-approval-of-moderna-s-mrna-flu-vaccine-mflusiva-amid-political-scrutiny 2026-08-05T16:50:03+00:00 hourly 0.9 https://trial.medpath.com/news/breast-milk-s-extraordinary-biology-how-hmos-iga-and-dha-shape-infant-gut-and-brain-development 2026-08-05T15:49:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breast-milk-s-extraordinary-biology-how-hmos-iga-and-dha-shape-infant-gut-and-brain-development 2026-08-05T15:49:14+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-and-abbvie-to-present-at-the-2026-wells-fargo-healthcare-conference 2026-08-05T14:50:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-and-abbvie-to-present-at-the-2026-wells-fargo-healthcare-conference 2026-08-05T14:50:19+00:00 hourly 0.9 https://trial.medpath.com/news/eton-pharmaceuticals-licenses-u-s-rights-to-asn-001-a-late-stage-topical-therapy-for-moderate-infantile-hemangiomas 2026-08-05T14:50:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eton-pharmaceuticals-licenses-u-s-rights-to-asn-001-a-late-stage-topical-therapy-for-moderate-infantile-hemangiomas 2026-08-05T14:50:11+00:00 hourly 0.9 https://trial.medpath.com/news/novel-two-part-drug-puts-cancer-cells-under-extreme-metabolic-stress-by-hijacking-sugar-and-blocking-fat 2026-08-05T14:49:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-two-part-drug-puts-cancer-cells-under-extreme-metabolic-stress-by-hijacking-sugar-and-blocking-fat 2026-08-05T14:49:26+00:00 hourly 0.9 https://trial.medpath.com/news/reckitt-s-mucinex-12hr-cold-fever-multi-symptom-receives-fda-approval-as-first-otc-cold-flu-innovation-in-14-years 2026-08-05T14:49:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reckitt-s-mucinex-12hr-cold-fever-multi-symptom-receives-fda-approval-as-first-otc-cold-flu-innovation-in-14-years 2026-08-05T14:49:25+00:00 hourly 0.9 https://trial.medpath.com/news/expedition-therapeutics-raises-115m-series-b-as-dpp1-inhibitor-expd-101-enters-phase-2-copd-trial 2026-08-05T13:49:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/expedition-therapeutics-raises-115m-series-b-as-dpp1-inhibitor-expd-101-enters-phase-2-copd-trial 2026-08-05T13:49:04+00:00 hourly 0.9 https://trial.medpath.com/news/cullinan-therapeutics-reports-53-7-million-q2-loss-missing-analyst-expectations 2026-08-05T12:49:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cullinan-therapeutics-reports-53-7-million-q2-loss-missing-analyst-expectations 2026-08-05T12:49:52+00:00 hourly 0.9 https://trial.medpath.com/news/large-scale-study-links-cyp2c19-genotype-to-specific-ssri-side-effects-and-discontinuation 2026-08-05T11:49:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-scale-study-links-cyp2c19-genotype-to-specific-ssri-side-effects-and-discontinuation 2026-08-05T11:49:36+00:00 hourly 0.9 https://trial.medpath.com/news/phase-ii-trial-of-atezolizumab-plus-bevacizumab-yields-nearly-40-response-rate-in-peritoneal-mesothelioma 2026-08-05T11:49:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-ii-trial-of-atezolizumab-plus-bevacizumab-yields-nearly-40-response-rate-in-peritoneal-mesothelioma 2026-08-05T11:49:27+00:00 hourly 0.9 https://trial.medpath.com/news/obsidian-therapeutics-enrolls-first-patient-in-registration-enabling-cohort-for-amsoki-cel-til-therapy-in-advanced-melanoma 2026-08-05T11:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/obsidian-therapeutics-enrolls-first-patient-in-registration-enabling-cohort-for-amsoki-cel-til-therapy-in-advanced-melanoma 2026-08-05T11:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-q2-2026-pharma-portfolio-renewal-gains-traction-as-nubeqa-and-kerendia-surge-66 2026-08-05T10:04:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-q2-2026-pharma-portfolio-renewal-gains-traction-as-nubeqa-and-kerendia-surge-66 2026-08-05T10:04:48+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-lifesciences-wins-usfda-approval-for-generic-indocyanine-green-injection-with-competitive-generic-therapy-designation 2026-08-05T10:04:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zydus-lifesciences-wins-usfda-approval-for-generic-indocyanine-green-injection-with-competitive-generic-therapy-designation 2026-08-05T10:04:17+00:00 hourly 0.9 https://trial.medpath.com/news/cell-and-gene-therapy-advances-outpace-healthcare-system-readiness 2026-08-05T10:04:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cell-and-gene-therapy-advances-outpace-healthcare-system-readiness 2026-08-05T10:04:14+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-initiates-phase-1-trial-of-oral-stat6-degrader-sar448272-triggering-10m-milestone-payment-to-nurix 2026-08-05T08:49:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-initiates-phase-1-trial-of-oral-stat6-degrader-sar448272-triggering-10m-milestone-payment-to-nurix 2026-08-05T08:49:45+00:00 hourly 0.9 https://trial.medpath.com/news/sandoz-q2-sales-beat-expectations-as-biosimilars-surge-22-ushering-in-a-golden-decade 2026-08-05T07:51:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sandoz-q2-sales-beat-expectations-as-biosimilars-surge-22-ushering-in-a-golden-decade 2026-08-05T07:51:43+00:00 hourly 0.9 https://trial.medpath.com/news/ai-is-helping-solve-the-intricate-genetic-puzzle-of-schizophrenia 2026-08-05T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-is-helping-solve-the-intricate-genetic-puzzle-of-schizophrenia 2026-08-05T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dragon-boat-paddling-offers-physical-and-psychosocial-healing-for-cancer-survivors 2026-08-05T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dragon-boat-paddling-offers-physical-and-psychosocial-healing-for-cancer-survivors 2026-08-05T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/blood-filtering-technique-for-cholesterol-also-removes-forever-chemicals-and-microplastics-study-finds 2026-08-05T03:50:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-filtering-technique-for-cholesterol-also-removes-forever-chemicals-and-microplastics-study-finds 2026-08-05T03:50:11+00:00 hourly 0.9 https://trial.medpath.com/news/tadalafil-long-term-use-linked-to-22-higher-glaucoma-risk-in-men-with-enlarged-prostates 2026-08-05T02:50:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tadalafil-long-term-use-linked-to-22-higher-glaucoma-risk-in-men-with-enlarged-prostates 2026-08-05T02:50:05+00:00 hourly 0.9 https://trial.medpath.com/news/chipotle-pulls-jalapenos-as-health-officials-investigate-salmonella-outbreak 2026-08-05T02:49:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chipotle-pulls-jalapenos-as-health-officials-investigate-salmonella-outbreak 2026-08-05T02:49:40+00:00 hourly 0.9 https://trial.medpath.com/news/iqvia-and-medera-forge-strategic-collaboration-to-accelerate-cardiac-gene-therapy-and-human-based-drug-discovery 2026-08-05T00:51:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iqvia-and-medera-forge-strategic-collaboration-to-accelerate-cardiac-gene-therapy-and-human-based-drug-discovery 2026-08-05T00:51:30+00:00 hourly 0.9 https://trial.medpath.com/news/tumor-like-tissue-microenvironments-could-hold-clues-to-curing-hiv-northwestern-study-finds 2026-08-04T23:50:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tumor-like-tissue-microenvironments-could-hold-clues-to-curing-hiv-northwestern-study-finds 2026-08-04T23:50:52+00:00 hourly 0.9 https://trial.medpath.com/news/breast-cancer-hijacks-immune-cells-to-recruit-tumor-fueling-nerves-ou-study-reveals 2026-08-04T21:52:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breast-cancer-hijacks-immune-cells-to-recruit-tumor-fueling-nerves-ou-study-reveals 2026-08-04T21:52:11+00:00 hourly 0.9 https://trial.medpath.com/news/blood-biomarker-amh-predicts-chemotherapy-benefit-in-premenopausal-women-with-hr-positive-breast-cancer 2026-08-04T20:53:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-biomarker-amh-predicts-chemotherapy-benefit-in-premenopausal-women-with-hr-positive-breast-cancer 2026-08-04T20:53:28+00:00 hourly 0.9 https://trial.medpath.com/news/eu-approves-label-extension-for-bavarian-nordic-s-imvanex-mpox-vaccine-to-children-aged-2-and-older 2026-08-04T19:50:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-approves-label-extension-for-bavarian-nordic-s-imvanex-mpox-vaccine-to-children-aged-2-and-older 2026-08-04T19:50:34+00:00 hourly 0.9 https://trial.medpath.com/news/enzene-launches-nextm-end-to-end-partnership-model-to-democratize-biologics-manufacturing-worldwide 2026-08-04T19:50:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enzene-launches-nextm-end-to-end-partnership-model-to-democratize-biologics-manufacturing-worldwide 2026-08-04T19:50:28+00:00 hourly 0.9 https://trial.medpath.com/news/three-essential-medicines-classified-as-carcinogenic-by-iarc-experts-urge-continued-treatment-with-monitoring 2026-08-04T19:50:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/three-essential-medicines-classified-as-carcinogenic-by-iarc-experts-urge-continued-treatment-with-monitoring 2026-08-04T19:50:10+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-chicago-medical-center-earns-u-s-news-best-hospital-honors-only-illinois-academic-medical-center-to-receive-community-access-designation 2026-08-04T18:49:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-chicago-medical-center-earns-u-s-news-best-hospital-honors-only-illinois-academic-medical-center-to-receive-community-access-designation 2026-08-04T18:49:06+00:00 hourly 0.9 https://trial.medpath.com/news/ladakh-set-to-become-india-s-first-region-to-complete-census-2027-by-september 2026-08-04T18:38:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ladakh-set-to-become-india-s-first-region-to-complete-census-2027-by-september 2026-08-04T18:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/insilico-medicine-uses-ai-to-map-molecular-landscape-and-identify-therapeutic-targets-for-rare-sinonasal-cancer 2026-08-04T17:50:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insilico-medicine-uses-ai-to-map-molecular-landscape-and-identify-therapeutic-targets-for-rare-sinonasal-cancer 2026-08-04T17:50:46+00:00 hourly 0.9 https://trial.medpath.com/news/3mdr-therapy-shows-promise-for-ptsd-with-traumatic-brain-injury-delivering-26-point-symptom-reduction 2026-08-04T17:50:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/3mdr-therapy-shows-promise-for-ptsd-with-traumatic-brain-injury-delivering-26-point-symptom-reduction 2026-08-04T17:50:42+00:00 hourly 0.9 https://trial.medpath.com/news/novel-mirna-129-based-therapy-achieves-over-95-tumor-shrinkage-in-preclinical-nsclc-model-halting-drug-resistance 2026-08-04T17:49:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-mirna-129-based-therapy-achieves-over-95-tumor-shrinkage-in-preclinical-nsclc-model-halting-drug-resistance 2026-08-04T17:49:55+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-names-tom-cavanaugh-to-lead-innovative-medicine-as-jennifer-taubert-retires-after-21-years 2026-08-04T16:51:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-names-tom-cavanaugh-to-lead-innovative-medicine-as-jennifer-taubert-retires-after-21-years 2026-08-04T16:51:24+00:00 hourly 0.9 https://trial.medpath.com/news/carsgen-s-allogeneic-bcma-car-t-ct0596-gains-nmpa-ind-approval-for-relapsed-refractory-multiple-myeloma 2026-08-04T16:50:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carsgen-s-allogeneic-bcma-car-t-ct0596-gains-nmpa-ind-approval-for-relapsed-refractory-multiple-myeloma 2026-08-04T16:50:52+00:00 hourly 0.9 https://trial.medpath.com/news/graymatters-health-taps-former-cigna-behavioral-health-executive-to-scale-payor-coverage-for-fda-cleared-prism-ptsd-therapy 2026-08-04T16:49:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/graymatters-health-taps-former-cigna-behavioral-health-executive-to-scale-payor-coverage-for-fda-cleared-prism-ptsd-therapy 2026-08-04T16:49:42+00:00 hourly 0.9 https://trial.medpath.com/news/uhealth-achieves-historic-gains-in-2026-2027-u-s-news-best-hospitals-rankings-led-by-25th-consecutive-no-1-for-ophthalmology 2026-08-04T16:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uhealth-achieves-historic-gains-in-2026-2027-u-s-news-best-hospitals-rankings-led-by-25th-consecutive-no-1-for-ophthalmology 2026-08-04T16:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/cirrus-therapeutics-secures-14-7m-seed-financing-and-seri-collaboration-to-advance-ocular-gene-therapy-for-geographic-atrophy 2026-08-04T15:50:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cirrus-therapeutics-secures-14-7m-seed-financing-and-seri-collaboration-to-advance-ocular-gene-therapy-for-geographic-atrophy 2026-08-04T15:50:23+00:00 hourly 0.9 https://trial.medpath.com/news/asp-isotopes-alpa-theranostics-to-advance-nanobody-powered-radiopharmaceuticals-into-clinical-trials-within-12-months 2026-08-04T15:50:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asp-isotopes-alpa-theranostics-to-advance-nanobody-powered-radiopharmaceuticals-into-clinical-trials-within-12-months 2026-08-04T15:50:19+00:00 hourly 0.9 https://trial.medpath.com/news/research-use-recombinant-protein-market-projected-to-reach-1-55-billion-by-2031-driven-by-expanding-drug-discovery-pipelines 2026-08-04T15:50:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/research-use-recombinant-protein-market-projected-to-reach-1-55-billion-by-2031-driven-by-expanding-drug-discovery-pipelines 2026-08-04T15:50:04+00:00 hourly 0.9 https://trial.medpath.com/news/entropy-neurodynamics-secures-ethics-approval-for-world-first-72-patient-basket-trial-of-iv-psilocin-across-eight-neuropsychiatric-indications 2026-08-04T15:49:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/entropy-neurodynamics-secures-ethics-approval-for-world-first-72-patient-basket-trial-of-iv-psilocin-across-eight-neuropsychiatric-indications 2026-08-04T15:49:03+00:00 hourly 0.9 https://trial.medpath.com/news/lower-vitamin-d-linked-to-mood-and-cognitive-impairment-in-adults-over-85-with-diabetes 2026-08-04T15:49:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lower-vitamin-d-linked-to-mood-and-cognitive-impairment-in-adults-over-85-with-diabetes 2026-08-04T15:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/cnd-life-sciences-secures-growth-financing-led-by-s-curve-partners-to-expand-syn-one-test-platform-for-neurodegenerative-diagnostics 2026-08-04T15:48:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cnd-life-sciences-secures-growth-financing-led-by-s-curve-partners-to-expand-syn-one-test-platform-for-neurodegenerative-diagnostics 2026-08-04T15:48:52+00:00 hourly 0.9 https://trial.medpath.com/news/ever-supreme-s-allogeneic-solid-tumor-car-t-car001-advances-to-phase-iia-targets-2028-taiwan-provisional-approval 2026-08-04T14:48:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ever-supreme-s-allogeneic-solid-tumor-car-t-car001-advances-to-phase-iia-targets-2028-taiwan-provisional-approval 2026-08-04T14:48:59+00:00 hourly 0.9 https://trial.medpath.com/news/hss-extends-record-breaking-streak-with-17th-consecutive-no-1-orthopedics-ranking-in-u-s-news-world-report 2026-08-04T13:51:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hss-extends-record-breaking-streak-with-17th-consecutive-no-1-orthopedics-ranking-in-u-s-news-world-report 2026-08-04T13:51:51+00:00 hourly 0.9 https://trial.medpath.com/news/risvodetinib-demonstrates-disease-modifying-biomarker-reversal-in-parkinson-s-disease-phase-2-trial 2026-08-04T13:51:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/risvodetinib-demonstrates-disease-modifying-biomarker-reversal-in-parkinson-s-disease-phase-2-trial 2026-08-04T13:51:32+00:00 hourly 0.9 https://trial.medpath.com/news/university-at-buffalo-faculty-spinouts-secure-nearly-16-million-in-2025-advancing-diagnostics-ai-and-therapeutics 2026-08-04T13:51:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-at-buffalo-faculty-spinouts-secure-nearly-16-million-in-2025-advancing-diagnostics-ai-and-therapeutics 2026-08-04T13:51:27+00:00 hourly 0.9 https://trial.medpath.com/news/evexta-bio-and-roche-ink-clinical-collaboration-to-evaluate-rupitasertib-plus-giredestrant-in-esr1-mutated-metastatic-breast-cancer 2026-08-04T12:49:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evexta-bio-and-roche-ink-clinical-collaboration-to-evaluate-rupitasertib-plus-giredestrant-in-esr1-mutated-metastatic-breast-cancer 2026-08-04T12:49:29+00:00 hourly 0.9 https://trial.medpath.com/news/marengo-nominates-first-tristar-drug-candidate-with-ipsen-appoints-t-cell-engager-expert-saso-cemerski 2026-08-04T12:49:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marengo-nominates-first-tristar-drug-candidate-with-ipsen-appoints-t-cell-engager-expert-saso-cemerski 2026-08-04T12:49:13+00:00 hourly 0.9 https://trial.medpath.com/news/mosaic-therapeutics-appoints-dr-allison-jeynes-as-chair-of-the-board-ahead-of-clinical-stage-transition 2026-08-04T10:49:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mosaic-therapeutics-appoints-dr-allison-jeynes-as-chair-of-the-board-ahead-of-clinical-stage-transition 2026-08-04T10:49:37+00:00 hourly 0.9 https://trial.medpath.com/news/inizio-launches-connected-insights-to-transform-global-medical-information-into-strategic-intelligence 2026-08-04T09:50:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inizio-launches-connected-insights-to-transform-global-medical-information-into-strategic-intelligence 2026-08-04T09:50:15+00:00 hourly 0.9 https://trial.medpath.com/news/the-second-act-of-thalidomide-from-teratogen-to-the-foundation-of-targeted-protein-degradation 2026-08-04T07:11:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-second-act-of-thalidomide-from-teratogen-to-the-foundation-of-targeted-protein-degradation 2026-08-04T07:11:06+00:00 hourly 0.9 https://trial.medpath.com/news/pathos-ai-licenses-experimental-triple-negative-breast-cancer-drug-from-china-s-alphamab-in-125-million-deal 2026-08-04T07:10:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pathos-ai-licenses-experimental-triple-negative-breast-cancer-drug-from-china-s-alphamab-in-125-million-deal 2026-08-04T07:10:11+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-menquadfi-wins-eu-approval-for-infants-from-six-weeks-of-age-against-invasive-meningococcal-disease 2026-08-04T07:08:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-s-menquadfi-wins-eu-approval-for-infants-from-six-weeks-of-age-against-invasive-meningococcal-disease 2026-08-04T07:08:54+00:00 hourly 0.9 https://trial.medpath.com/news/colorado-teacher-marks-10-years-in-complete-remission-after-pioneering-car-t-cell-therapy-at-nebraska-medical-center 2026-08-04T07:08:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/colorado-teacher-marks-10-years-in-complete-remission-after-pioneering-car-t-cell-therapy-at-nebraska-medical-center 2026-08-04T07:08:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-assigns-class-i-recall-to-impella-heart-pump-introducer-kits-over-bleeding-risk 2026-08-04T06:08:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-assigns-class-i-recall-to-impella-heart-pump-introducer-kits-over-bleeding-risk 2026-08-04T06:08:36+00:00 hourly 0.9 https://trial.medpath.com/news/iol-chemicals-pharmaceuticals-concludes-39th-agm-approves-fy26-financials-and-director-re-appointment 2026-08-04T04:09:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iol-chemicals-pharmaceuticals-concludes-39th-agm-approves-fy26-financials-and-director-re-appointment 2026-08-04T04:09:01+00:00 hourly 0.9 https://trial.medpath.com/news/korean-drugmakers-pivot-to-digital-healthcare-as-generic-price-cuts-squeeze-profitability 2026-08-04T03:07:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/korean-drugmakers-pivot-to-digital-healthcare-as-generic-price-cuts-squeeze-profitability 2026-08-04T03:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/nicotine-free-vapes-found-to-contain-nicotine-and-unverified-analogues-exposing-regulatory-blind-spot-in-south-korea 2026-08-04T00:09:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nicotine-free-vapes-found-to-contain-nicotine-and-unverified-analogues-exposing-regulatory-blind-spot-in-south-korea 2026-08-04T00:09:13+00:00 hourly 0.9 https://trial.medpath.com/news/cellular-basis-of-hfpef-abnormal-lipids-and-the-emerging-role-of-electronegative-vldl-v5 2026-08-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellular-basis-of-hfpef-abnormal-lipids-and-the-emerging-role-of-electronegative-vldl-v5 2026-08-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/former-openai-exec-fidji-simo-launches-chroniclebio-to-tackle-pots-and-chronic-diseases-using-ai-driven-subtyping 2026-08-03T23:08:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/former-openai-exec-fidji-simo-launches-chroniclebio-to-tackle-pots-and-chronic-diseases-using-ai-driven-subtyping 2026-08-03T23:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/three-daily-servings-of-full-fat-dairy-show-no-adverse-metabolic-effects-in-overweight-adults-study-finds 2026-08-03T22:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/three-daily-servings-of-full-fat-dairy-show-no-adverse-metabolic-effects-in-overweight-adults-study-finds 2026-08-03T22:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/lingo1-targeted-antibody-drug-conjugates-show-preclinical-efficacy-and-tolerability-in-ewing-sarcoma-models 2026-08-03T22:08:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lingo1-targeted-antibody-drug-conjugates-show-preclinical-efficacy-and-tolerability-in-ewing-sarcoma-models 2026-08-03T22:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/california-supreme-court-rules-drugmakers-have-no-duty-to-innovate-in-landmark-gilead-hiv-drug-case 2026-08-03T22:08:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/california-supreme-court-rules-drugmakers-have-no-duty-to-innovate-in-landmark-gilead-hiv-drug-case 2026-08-03T22:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/locally-acquired-dengue-fever-cases-confirmed-in-palm-beach-and-miami-dade-counties-florida-health-officials-issue-mosquito-protection-alert 2026-08-03T22:08:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/locally-acquired-dengue-fever-cases-confirmed-in-palm-beach-and-miami-dade-counties-florida-health-officials-issue-mosquito-protection-alert 2026-08-03T22:08:17+00:00 hourly 0.9 https://trial.medpath.com/news/esophageal-cancer-market-poised-for-6-cagr-growth-through-2036-driven-by-adc-and-immunotherapy-innovation 2026-08-03T21:09:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esophageal-cancer-market-poised-for-6-cagr-growth-through-2036-driven-by-adc-and-immunotherapy-innovation 2026-08-03T21:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/third-meeting-of-the-advisory-council-on-parkinson-s-research-care-and-services-set-for-november-2026 2026-08-03T21:08:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/third-meeting-of-the-advisory-council-on-parkinson-s-research-care-and-services-set-for-november-2026 2026-08-03T21:08:36+00:00 hourly 0.9 https://trial.medpath.com/news/survey-reveals-patients-with-nonmelanoma-skin-cancer-prioritize-cure-rates-and-nonsurgical-options-demand-greater-autonomy-over-insurance-driven-decisions 2026-08-03T21:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/survey-reveals-patients-with-nonmelanoma-skin-cancer-prioritize-cure-rates-and-nonsurgical-options-demand-greater-autonomy-over-insurance-driven-decisions 2026-08-03T21:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/wellspan-expands-cancer-care-access-in-central-susquehanna-valley-with-phased-oncology-investment 2026-08-03T21:08:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wellspan-expands-cancer-care-access-in-central-susquehanna-valley-with-phased-oncology-investment 2026-08-03T21:08:33+00:00 hourly 0.9 https://trial.medpath.com/news/global-drug-reference-apps-market-to-reach-usd-3-70-billion-by-2034-driven-by-ai-powered-search-and-ehr-integration 2026-08-03T21:08:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-drug-reference-apps-market-to-reach-usd-3-70-billion-by-2034-driven-by-ai-powered-search-and-ehr-integration 2026-08-03T21:08:31+00:00 hourly 0.9 https://trial.medpath.com/news/randomized-u-s-trial-finds-autonomous-oxygen-system-significantly-improves-precision-of-hospital-oxygen-therapy 2026-08-03T20:11:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/randomized-u-s-trial-finds-autonomous-oxygen-system-significantly-improves-precision-of-hospital-oxygen-therapy 2026-08-03T20:11:44+00:00 hourly 0.9 https://trial.medpath.com/news/menarini-asia-pacific-to-commercialise-cosela-trilaciclib-across-multiple-apac-markets-first-launch-anticipated-in-hong-kong-in-2028 2026-08-03T20:11:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/menarini-asia-pacific-to-commercialise-cosela-trilaciclib-across-multiple-apac-markets-first-launch-anticipated-in-hong-kong-in-2028 2026-08-03T20:11:36+00:00 hourly 0.9 https://trial.medpath.com/news/utc-launches-clinical-addiction-studies-certificate-to-address-projected-shortage-of-123000-addiction-counselors-by-2038 2026-08-03T20:11:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/utc-launches-clinical-addiction-studies-certificate-to-address-projected-shortage-of-123000-addiction-counselors-by-2038 2026-08-03T20:11:33+00:00 hourly 0.9 https://trial.medpath.com/news/2026-guidelines-target-immune-checkpoint-inhibitor-associated-myocarditis-a-complication-with-37-50-mortality 2026-08-03T19:14:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/2026-guidelines-target-immune-checkpoint-inhibitor-associated-myocarditis-a-complication-with-37-50-mortality 2026-08-03T19:14:25+00:00 hourly 0.9 https://trial.medpath.com/news/servier-builds-rare-neurology-pipeline-from-the-ground-up-under-new-r-d-leadership 2026-08-03T19:12:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/servier-builds-rare-neurology-pipeline-from-the-ground-up-under-new-r-d-leadership 2026-08-03T19:12:51+00:00 hourly 0.9 https://trial.medpath.com/news/global-survey-reveals-over-80-of-cancer-providers-lack-knowledge-to-recommend-integrative-oncology-therapies 2026-08-03T18:08:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-survey-reveals-over-80-of-cancer-providers-lack-knowledge-to-recommend-integrative-oncology-therapies 2026-08-03T18:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/molecure-s-oatd-01-clears-idmc-interim-analysis-in-phase-ii-pulmonary-sarcoidosis-trial 2026-08-03T17:11:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/molecure-s-oatd-01-clears-idmc-interim-analysis-in-phase-ii-pulmonary-sarcoidosis-trial 2026-08-03T17:11:06+00:00 hourly 0.9 https://trial.medpath.com/news/palmer-s-launches-lemon-sorbet-body-care-collection-combining-brightening-ingredients-with-fragrance-forward-appeal 2026-08-03T17:11:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/palmer-s-launches-lemon-sorbet-body-care-collection-combining-brightening-ingredients-with-fragrance-forward-appeal 2026-08-03T17:11:01+00:00 hourly 0.9 https://trial.medpath.com/news/akebia-doses-first-patient-in-phase-2-basket-trial-of-ebribafusp-for-rare-complement-mediated-kidney-diseases 2026-08-03T17:08:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akebia-doses-first-patient-in-phase-2-basket-trial-of-ebribafusp-for-rare-complement-mediated-kidney-diseases 2026-08-03T17:08:48+00:00 hourly 0.9 https://trial.medpath.com/news/ai-model-uncovers-hidden-health-risks-in-routine-sleep-study-data-doubling-mortality-prediction-accuracy 2026-08-03T17:08:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-model-uncovers-hidden-health-risks-in-routine-sleep-study-data-doubling-mortality-prediction-accuracy 2026-08-03T17:08:45+00:00 hourly 0.9 https://trial.medpath.com/news/dash-bio-raises-30m-series-a-to-modernize-bioanalysis-and-accelerate-drug-development-timelines 2026-08-03T16:09:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dash-bio-raises-30m-series-a-to-modernize-bioanalysis-and-accelerate-drug-development-timelines 2026-08-03T16:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/mech-seqtm-technology-enables-industrial-scale-screening-of-drug-candidates-by-measuring-functional-efficacy-beyond-binding 2026-08-03T16:08:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mech-seqtm-technology-enables-industrial-scale-screening-of-drug-candidates-by-measuring-functional-efficacy-beyond-binding 2026-08-03T16:08:47+00:00 hourly 0.9 https://trial.medpath.com/news/nagoya-university-study-reveals-orexin-neurons-as-key-drivers-of-sustained-motivation 2026-08-03T16:08:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nagoya-university-study-reveals-orexin-neurons-as-key-drivers-of-sustained-motivation 2026-08-03T16:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/dr-reddy-s-registers-pd-1-immunotherapy-in-south-africa-for-rare-nasopharyngeal-carcinoma 2026-08-03T16:08:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dr-reddy-s-registers-pd-1-immunotherapy-in-south-africa-for-rare-nasopharyngeal-carcinoma 2026-08-03T16:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/simparo-surgical-secures-fourth-u-s-patent-for-novel-suture-locking-mechanism-in-thumb-cmc-reconstruction 2026-08-03T15:10:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/simparo-surgical-secures-fourth-u-s-patent-for-novel-suture-locking-mechanism-in-thumb-cmc-reconstruction 2026-08-03T15:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/korsana-biosciences-goes-public-with-usd-380m-raise-as-alzheimer-s-antibody-krsa-028-heads-toward-phase-i 2026-08-03T15:10:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/korsana-biosciences-goes-public-with-usd-380m-raise-as-alzheimer-s-antibody-krsa-028-heads-toward-phase-i 2026-08-03T15:10:01+00:00 hourly 0.9 https://trial.medpath.com/news/genezen-and-raiden-science-foundation-partner-to-advance-first-aav9-gene-replacement-therapy-for-uba5-disorder-toward-clinical-trial 2026-08-03T15:09:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genezen-and-raiden-science-foundation-partner-to-advance-first-aav9-gene-replacement-therapy-for-uba5-disorder-toward-clinical-trial 2026-08-03T15:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/ceruvia-raises-8-million-to-advance-non-hallucinogenic-lsd-analog-bol-148-into-integrated-phase-1-2-trial-for-cluster-headache 2026-08-03T15:09:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ceruvia-raises-8-million-to-advance-non-hallucinogenic-lsd-analog-bol-148-into-integrated-phase-1-2-trial-for-cluster-headache 2026-08-03T15:09:57+00:00 hourly 0.9 https://trial.medpath.com/news/arginine-supplementation-emerges-as-a-simple-strategy-to-boost-immune-surveillance-against-cancer-and-viruses 2026-08-03T15:09:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arginine-supplementation-emerges-as-a-simple-strategy-to-boost-immune-surveillance-against-cancer-and-viruses 2026-08-03T15:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/sandoz-agrees-to-450-million-settlement-with-43-us-states-over-generic-drug-antitrust-claims 2026-08-03T15:09:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sandoz-agrees-to-450-million-settlement-with-43-us-states-over-generic-drug-antitrust-claims 2026-08-03T15:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/lantern-pharma-spins-out-open-medicine-ai-to-commercialize-its-multi-agent-ai-co-scientist-platform 2026-08-03T15:07:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lantern-pharma-spins-out-open-medicine-ai-to-commercialize-its-multi-agent-ai-co-scientist-platform 2026-08-03T15:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-class-adar1-inhibitor-rebecsinib-enters-phase-1-trial-for-aml-and-myelofibrosis-at-uc-san-diego 2026-08-03T14:09:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-in-class-adar1-inhibitor-rebecsinib-enters-phase-1-trial-for-aml-and-myelofibrosis-at-uc-san-diego 2026-08-03T14:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-medicine-news-and-chinese-society-of-gene-cell-therapy-form-media-partnership-to-bridge-global-gene-editing-research 2026-08-03T13:07:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-medicine-news-and-chinese-society-of-gene-cell-therapy-form-media-partnership-to-bridge-global-gene-editing-research 2026-08-03T13:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/ratio-therapeutics-secures-70m-series-c-to-advance-radiopharmaceutical-pipeline-led-by-fap-targeted-candidate 2026-08-03T12:08:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ratio-therapeutics-secures-70m-series-c-to-advance-radiopharmaceutical-pipeline-led-by-fap-targeted-candidate 2026-08-03T12:08:27+00:00 hourly 0.9 https://trial.medpath.com/news/weight-loss-alone-may-not-prevent-type-2-diabetes-in-high-risk-metabolic-cluster-study-finds 2026-08-03T11:09:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/weight-loss-alone-may-not-prevent-type-2-diabetes-in-high-risk-metabolic-cluster-study-finds 2026-08-03T11:09:03+00:00 hourly 0.9 https://trial.medpath.com/news/pilatus-biosciences-secures-u-s-patent-allowance-and-worldwide-ip-rights-for-cd36-targeted-cancer-therapy-plt012 2026-08-03T11:08:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pilatus-biosciences-secures-u-s-patent-allowance-and-worldwide-ip-rights-for-cd36-targeted-cancer-therapy-plt012 2026-08-03T11:08:37+00:00 hourly 0.9 https://trial.medpath.com/news/culturally-adapted-lifestyle-program-boosts-cognition-55-more-in-older-adults-at-risk-of-dementia 2026-08-03T11:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/culturally-adapted-lifestyle-program-boosts-cognition-55-more-in-older-adults-at-risk-of-dementia 2026-08-03T11:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/intranasal-dexmedetomidine-the-night-before-surgery-halves-postoperative-delirium-in-older-arthroplasty-patients 2026-08-03T09:11:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intranasal-dexmedetomidine-the-night-before-surgery-halves-postoperative-delirium-in-older-arthroplasty-patients 2026-08-03T09:11:28+00:00 hourly 0.9 https://trial.medpath.com/news/aravax-awarded-fda-fast-track-designation-for-pvx108-a-next-generation-peptide-immunotherapy-for-peanut-allergy 2026-08-03T09:11:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aravax-awarded-fda-fast-track-designation-for-pvx108-a-next-generation-peptide-immunotherapy-for-peanut-allergy 2026-08-03T09:11:21+00:00 hourly 0.9 https://trial.medpath.com/news/intratumoral-fusobacterium-identified-as-prognostic-and-predictive-biomarker-in-resectable-colorectal-cancer 2026-08-03T07:10:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intratumoral-fusobacterium-identified-as-prognostic-and-predictive-biomarker-in-resectable-colorectal-cancer 2026-08-03T07:10:03+00:00 hourly 0.9 https://trial.medpath.com/news/multi-omics-profiling-reveals-distinct-molecular-identities-across-four-autoimmune-diseases 2026-08-03T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multi-omics-profiling-reveals-distinct-molecular-identities-across-four-autoimmune-diseases 2026-08-03T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/persistent-cytolytic-cd8-t-cells-found-across-multiple-viral-specificities-in-long-covid 2026-08-03T06:08:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/persistent-cytolytic-cd8-t-cells-found-across-multiple-viral-specificities-in-long-covid 2026-08-03T06:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/chabiotech-and-ewha-womans-university-launch-government-backed-project-to-develop-first-in-class-autologous-stem-cell-therapy-for-peritoneal-fibrosis 2026-08-03T06:08:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chabiotech-and-ewha-womans-university-launch-government-backed-project-to-develop-first-in-class-autologous-stem-cell-therapy-for-peritoneal-fibrosis 2026-08-03T06:08:55+00:00 hourly 0.9 https://trial.medpath.com/news/daily-tomato-consumption-linked-to-greater-reduction-in-liver-fat-in-masld-exploratory-trial 2026-08-03T06:08:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daily-tomato-consumption-linked-to-greater-reduction-in-liver-fat-in-masld-exploratory-trial 2026-08-03T06:08:48+00:00 hourly 0.9 https://trial.medpath.com/news/common-nasal-decongestant-oxymetazoline-emerges-as-surprising-longevity-candidate 2026-08-03T05:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/common-nasal-decongestant-oxymetazoline-emerges-as-surprising-longevity-candidate 2026-08-03T05:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/hong-kong-trial-tests-controversial-surgery-for-alzheimer-s-patients-after-china-bans-unregulated-use 2026-08-03T05:08:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hong-kong-trial-tests-controversial-surgery-for-alzheimer-s-patients-after-china-bans-unregulated-use 2026-08-03T05:08:37+00:00 hourly 0.9 https://trial.medpath.com/news/cspc-s-ha1406-hits-primary-endpoint-in-phase-iii-depression-trial 2026-08-03T03:17:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cspc-s-ha1406-hits-primary-endpoint-in-phase-iii-depression-trial 2026-08-03T03:17:25+00:00 hourly 0.9 https://trial.medpath.com/news/persistent-financial-hardship-linked-to-poorer-memory-slower-processing-speed-and-accelerated-brain-aging-by-midlife 2026-08-03T03:17:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/persistent-financial-hardship-linked-to-poorer-memory-slower-processing-speed-and-accelerated-brain-aging-by-midlife 2026-08-03T03:17:12+00:00 hourly 0.9 https://trial.medpath.com/news/popular-artificial-sweeteners-linked-to-faster-brain-aging-in-large-observational-study 2026-08-03T02:09:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/popular-artificial-sweeteners-linked-to-faster-brain-aging-in-large-observational-study 2026-08-03T02:09:21+00:00 hourly 0.9 https://trial.medpath.com/news/congress-moves-to-block-white-house-plan-to-politicize-federal-research-grants 2026-08-03T02:08:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/congress-moves-to-block-white-house-plan-to-politicize-federal-research-grants 2026-08-03T02:08:57+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-to-acquire-ataibeckley-for-up-to-3-8-billion-in-landmark-psychedelic-medicine-deal 2026-08-03T01:07:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-to-acquire-ataibeckley-for-up-to-3-8-billion-in-landmark-psychedelic-medicine-deal 2026-08-03T01:07:39+00:00 hourly 0.9 https://trial.medpath.com/news/actor-ethan-suplee-warns-glp-1-weight-loss-drugs-are-not-a-one-stop-shop-for-lasting-results 2026-08-02T23:08:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actor-ethan-suplee-warns-glp-1-weight-loss-drugs-are-not-a-one-stop-shop-for-lasting-results 2026-08-02T23:08:02+00:00 hourly 0.9 https://trial.medpath.com/news/injectable-biomaterial-turns-stroke-cavities-into-repair-hubs-restoring-motor-function-in-mice 2026-08-02T23:07:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/injectable-biomaterial-turns-stroke-cavities-into-repair-hubs-restoring-motor-function-in-mice 2026-08-02T23:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/brazil-rises-to-2nd-worldwide-in-clinical-trial-recruitment-driven-by-execution-and-population-diversity 2026-08-02T23:07:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brazil-rises-to-2nd-worldwide-in-clinical-trial-recruitment-driven-by-execution-and-population-diversity 2026-08-02T23:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/creatine-supplementation-for-brain-health-consistency-over-timing-experts-say 2026-08-02T22:08:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/creatine-supplementation-for-brain-health-consistency-over-timing-experts-say 2026-08-02T22:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/mezzion-reports-positive-in-vivo-results-for-pde5-inhibitor-udenafil-in-adpkd-plans-phase-2b-trial 2026-08-02T21:10:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mezzion-reports-positive-in-vivo-results-for-pde5-inhibitor-udenafil-in-adpkd-plans-phase-2b-trial 2026-08-02T21:10:19+00:00 hourly 0.9 https://trial.medpath.com/news/senate-spending-bill-delays-federal-recriminalization-of-hemp-thc-products-offering-reprieve-to-28-billion-industry 2026-08-02T21:10:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senate-spending-bill-delays-federal-recriminalization-of-hemp-thc-products-offering-reprieve-to-28-billion-industry 2026-08-02T21:10:18+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-explores-megadeal-merger-with-bristol-myers-squibb-in-potential-400-billion-pharma-combination 2026-08-02T21:09:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-explores-megadeal-merger-with-bristol-myers-squibb-in-potential-400-billion-pharma-combination 2026-08-02T21:09:32+00:00 hourly 0.9 https://trial.medpath.com/news/original-medicare-s-uncapped-20-coinsurance-can-turn-a-cancer-year-into-tens-of-thousands-in-out-of-pocket-costs 2026-08-02T21:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/original-medicare-s-uncapped-20-coinsurance-can-turn-a-cancer-year-into-tens-of-thousands-in-out-of-pocket-costs 2026-08-02T21:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/childhood-vaccine-hesitancy-rises-as-u-s-measles-cases-hit-30-year-high-amid-policy-shifts 2026-08-02T20:09:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/childhood-vaccine-hesitancy-rises-as-u-s-measles-cases-hit-30-year-high-amid-policy-shifts 2026-08-02T20:09:02+00:00 hourly 0.9 https://trial.medpath.com/news/michigan-supreme-court-narrows-regulatory-exemption-clearing-path-for-insulin-pricing-investigation-against-eli-lilly 2026-08-02T19:10:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/michigan-supreme-court-narrows-regulatory-exemption-clearing-path-for-insulin-pricing-investigation-against-eli-lilly 2026-08-02T19:10:04+00:00 hourly 0.9 https://trial.medpath.com/news/measles-cases-hit-35-year-us-high-as-hhs-secretary-kennedy-challenges-vaccine-science-on-national-television 2026-08-02T19:09:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/measles-cases-hit-35-year-us-high-as-hhs-secretary-kennedy-challenges-vaccine-science-on-national-television 2026-08-02T19:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/greg-papa-s-return-to-49ers-booth-uncertain-after-78-day-icu-stay-and-life-threatening-post-transplant-complications 2026-08-02T19:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/greg-papa-s-return-to-49ers-booth-uncertain-after-78-day-icu-stay-and-life-threatening-post-transplant-complications 2026-08-02T19:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/ai-driven-drug-discovery-and-personalized-cancer-vaccines-signal-a-new-era-in-medicine 2026-08-02T18:08:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-driven-drug-discovery-and-personalized-cancer-vaccines-signal-a-new-era-in-medicine 2026-08-02T18:08:33+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-discloses-major-patient-data-breach-via-third-party-cloud-vendors-shinyhunters-suspected 2026-08-02T18:08:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-discloses-major-patient-data-breach-via-third-party-cloud-vendors-shinyhunters-suspected 2026-08-02T18:08:04+00:00 hourly 0.9 https://trial.medpath.com/news/secondhand-smoke-linked-to-67-higher-sleep-arousal-index-in-children-study-finds 2026-08-02T18:07:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/secondhand-smoke-linked-to-67-higher-sleep-arousal-index-in-children-study-finds 2026-08-02T18:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/w-a-s-p-guitarist-chris-holmes-begins-radiotherapy-for-prostate-cancer-amid-insurance-coverage-gaps 2026-08-02T17:08:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/w-a-s-p-guitarist-chris-holmes-begins-radiotherapy-for-prostate-cancer-amid-insurance-coverage-gaps 2026-08-02T17:08:52+00:00 hourly 0.9 https://trial.medpath.com/news/florida-reports-record-36-leprosy-cases-in-2025-central-florida-remains-epicenter 2026-08-02T17:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/florida-reports-record-36-leprosy-cases-in-2025-central-florida-remains-epicenter 2026-08-02T17:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/senators-demand-answers-on-rfk-jr-s-financial-ties-to-merck-s-50-million-gardasil-settlement 2026-08-02T16:08:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senators-demand-answers-on-rfk-jr-s-financial-ties-to-merck-s-50-million-gardasil-settlement 2026-08-02T16:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/multiple-myeloma-in-2026-mrd-guided-approval-quadruplet-frontline-therapy-and-immunotherapy-moving-earlier 2026-08-02T16:08:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multiple-myeloma-in-2026-mrd-guided-approval-quadruplet-frontline-therapy-and-immunotherapy-moving-earlier 2026-08-02T16:08:09+00:00 hourly 0.9 https://trial.medpath.com/news/new-chemotherapy-free-immunotherapy-combination-for-follicular-lymphoma-listed-on-the-pbs 2026-08-02T16:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-chemotherapy-free-immunotherapy-combination-for-follicular-lymphoma-listed-on-the-pbs 2026-08-02T16:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/nccs-appoints-alexandre-chan-as-director-of-cancer-survivorship-and-wellness 2026-08-02T14:08:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nccs-appoints-alexandre-chan-as-director-of-cancer-survivorship-and-wellness 2026-08-02T14:08:07+00:00 hourly 0.9 https://trial.medpath.com/news/cellorigin-unveils-two-novel-solid-tumor-cell-therapy-platforms-at-asco-2026-and-partners-with-walvax-for-in-vivo-car-t-clinical-trial 2026-08-02T12:07:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellorigin-unveils-two-novel-solid-tumor-cell-therapy-platforms-at-asco-2026-and-partners-with-walvax-for-in-vivo-car-t-clinical-trial 2026-08-02T12:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/nyu-langone-and-dana-farber-co-develop-solavia-decision-suite-a-next-generation-oncology-clinical-decision-support-platform 2026-08-02T11:09:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nyu-langone-and-dana-farber-co-develop-solavia-decision-suite-a-next-generation-oncology-clinical-decision-support-platform 2026-08-02T11:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/world-lung-cancer-day-highlights-critical-gaps-in-early-screening-as-lung-cancer-remains-deadliest-cancer 2026-08-02T11:08:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-lung-cancer-day-highlights-critical-gaps-in-early-screening-as-lung-cancer-remains-deadliest-cancer 2026-08-02T11:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/t-cell-redirecting-therapies-reshape-the-future-of-lung-cancer-treatment 2026-08-02T10:08:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/t-cell-redirecting-therapies-reshape-the-future-of-lung-cancer-treatment 2026-08-02T10:08:05+00:00 hourly 0.9 https://trial.medpath.com/news/first-new-treatment-for-rare-brain-cancer-in-20-years-added-to-australia-s-pbs 2026-08-02T05:33:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-new-treatment-for-rare-brain-cancer-in-20-years-added-to-australia-s-pbs 2026-08-02T05:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/eib-backs-aiforia-with-eur20-million-venture-debt-to-accelerate-ai-powered-cancer-diagnostics 2026-08-02T05:32:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eib-backs-aiforia-with-eur20-million-venture-debt-to-accelerate-ai-powered-cancer-diagnostics 2026-08-02T05:32:19+00:00 hourly 0.9 https://trial.medpath.com/news/phase-iii-trial-shows-silver-diamine-fluoride-halts-cavities-in-over-half-of-young-children-without-drilling 2026-08-02T05:30:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-iii-trial-shows-silver-diamine-fluoride-halts-cavities-in-over-half-of-young-children-without-drilling 2026-08-02T05:30:33+00:00 hourly 0.9 https://trial.medpath.com/news/stage-4-lung-cancer-is-no-longer-a-death-sentence-how-precision-oncology-and-immunotherapy-have-transformed-treatment 2026-08-02T05:30:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stage-4-lung-cancer-is-no-longer-a-death-sentence-how-precision-oncology-and-immunotherapy-have-transformed-treatment 2026-08-02T05:30:09+00:00 hourly 0.9 https://trial.medpath.com/news/td-cowen-initiates-buy-rating-on-abbvie-with-280-price-target 2026-08-02T01:07:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/td-cowen-initiates-buy-rating-on-abbvie-with-280-price-target 2026-08-02T01:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/trf2-reveals-dual-role-as-guardian-of-muscle-stem-cell-identity-and-regeneration 2026-08-02T00:07:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trf2-reveals-dual-role-as-guardian-of-muscle-stem-cell-identity-and-regeneration 2026-08-02T00:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/pm-modi-launches-100-week-nationwide-youth-campaign-against-drug-abuse 2026-08-01T23:13:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pm-modi-launches-100-week-nationwide-youth-campaign-against-drug-abuse 2026-08-01T23:13:59+00:00 hourly 0.9 https://trial.medpath.com/news/sperm-cooperation-not-competition-drives-fertilization-success-across-arthropods-landmark-study-reveals 2026-08-01T23:13:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sperm-cooperation-not-competition-drives-fertilization-success-across-arthropods-landmark-study-reveals 2026-08-01T23:13:38+00:00 hourly 0.9 https://trial.medpath.com/news/bio-sensing-technologies-poised-to-transform-precision-medicine-as-market-projected-to-reach-23-21-billion-by-2035 2026-08-01T23:11:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bio-sensing-technologies-poised-to-transform-precision-medicine-as-market-projected-to-reach-23-21-billion-by-2035 2026-08-01T23:11:23+00:00 hourly 0.9 https://trial.medpath.com/news/north-america-prefilled-syringes-market-to-reach-usd-17-46-billion-by-2035-driven-by-biologics-and-home-self-administration 2026-08-01T23:11:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/north-america-prefilled-syringes-market-to-reach-usd-17-46-billion-by-2035-driven-by-biologics-and-home-self-administration 2026-08-01T23:11:20+00:00 hourly 0.9 https://trial.medpath.com/news/seven-days-of-antibiotics-matches-14-days-for-uncomplicated-gram-negative-bacteremia-evidence-review-concludes 2026-08-01T23:11:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seven-days-of-antibiotics-matches-14-days-for-uncomplicated-gram-negative-bacteremia-evidence-review-concludes 2026-08-01T23:11:05+00:00 hourly 0.9 https://trial.medpath.com/news/triple-drug-antihypertensive-single-pill-combinations-added-to-who-essential-medicines-list 2026-08-01T19:12:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/triple-drug-antihypertensive-single-pill-combinations-added-to-who-essential-medicines-list 2026-08-01T19:12:50+00:00 hourly 0.9 https://trial.medpath.com/news/cbn-seizes-66-80-lakh-psychotropic-tablets-in-major-inter-state-pharmaceutical-diversion-bust 2026-08-01T19:11:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cbn-seizes-66-80-lakh-psychotropic-tablets-in-major-inter-state-pharmaceutical-diversion-bust 2026-08-01T19:11:54+00:00 hourly 0.9 https://trial.medpath.com/news/ai-speech-analysis-predicts-adolescent-mental-health-disorders-years-before-onset-outperforming-clinical-experts 2026-08-01T19:11:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-speech-analysis-predicts-adolescent-mental-health-disorders-years-before-onset-outperforming-clinical-experts 2026-08-01T19:11:54+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-recreate-deadly-plant-compounds-in-the-lab-opening-door-to-new-therapeutics 2026-08-01T19:10:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-recreate-deadly-plant-compounds-in-the-lab-opening-door-to-new-therapeutics 2026-08-01T19:10:57+00:00 hourly 0.9 https://trial.medpath.com/news/proton-beam-therapy-halts-recurrent-spinal-ependymoma-after-three-surgeries-a-singapore-case-study 2026-08-01T19:10:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proton-beam-therapy-halts-recurrent-spinal-ependymoma-after-three-surgeries-a-singapore-case-study 2026-08-01T19:10:54+00:00 hourly 0.9 https://trial.medpath.com/news/immune-navigation-system-discovery-reveals-novel-drug-target-for-chronic-inflammatory-diseases 2026-08-01T19:10:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immune-navigation-system-discovery-reveals-novel-drug-target-for-chronic-inflammatory-diseases 2026-08-01T19:10:10+00:00 hourly 0.9 https://trial.medpath.com/news/magnitude-7-1-earthquake-in-japan-s-kyushu-leaves-34-dead-as-survivors-face-water-fuel-shortages-and-extreme-heat 2026-08-01T18:09:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/magnitude-7-1-earthquake-in-japan-s-kyushu-leaves-34-dead-as-survivors-face-water-fuel-shortages-and-extreme-heat 2026-08-01T18:09:36+00:00 hourly 0.9 https://trial.medpath.com/news/option-care-health-q2-acute-portfolio-momentum-and-cid-stabilization-drive-earnings-beat 2026-08-01T18:09:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/option-care-health-q2-acute-portfolio-momentum-and-cid-stabilization-drive-earnings-beat 2026-08-01T18:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/federal-survey-reveals-declining-substance-use-and-improved-mental-health-among-u-s-youth 2026-08-01T18:09:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-survey-reveals-declining-substance-use-and-improved-mental-health-among-u-s-youth 2026-08-01T18:09:28+00:00 hourly 0.9 https://trial.medpath.com/news/bacterial-protein-fragment-corisin-identified-as-a-causal-driver-of-pulmonary-fibrosis-and-a-promising-therapeutic-target 2026-08-01T18:09:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bacterial-protein-fragment-corisin-identified-as-a-causal-driver-of-pulmonary-fibrosis-and-a-promising-therapeutic-target 2026-08-01T18:09:27+00:00 hourly 0.9 https://trial.medpath.com/news/brazil-s-booming-black-market-for-glp-1-weight-loss-drugs-raises-safety-alarms 2026-08-01T18:09:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brazil-s-booming-black-market-for-glp-1-weight-loss-drugs-raises-safety-alarms 2026-08-01T18:09:03+00:00 hourly 0.9 https://trial.medpath.com/news/language-barriers-put-cald-australians-at-heightened-risk-of-medicine-harm-psa-report-finds 2026-08-01T18:09:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/language-barriers-put-cald-australians-at-heightened-risk-of-medicine-harm-psa-report-finds 2026-08-01T18:09:01+00:00 hourly 0.9 https://trial.medpath.com/news/quantum-trial-tests-teclistamab-after-stem-cell-transplantation-for-primary-plasma-cell-leukemia 2026-08-01T16:11:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quantum-trial-tests-teclistamab-after-stem-cell-transplantation-for-primary-plasma-cell-leukemia 2026-08-01T16:11:10+00:00 hourly 0.9 https://trial.medpath.com/news/caredx-raises-full-year-guidance-as-transplant-diagnostics-revenue-surges-52 2026-08-01T16:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caredx-raises-full-year-guidance-as-transplant-diagnostics-revenue-surges-52 2026-08-01T16:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/bruntwood-scitech-completes-ps60m-greenheys-lab-ushering-uk-biobank-s-new-manchester-headquarters 2026-08-01T16:10:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bruntwood-scitech-completes-ps60m-greenheys-lab-ushering-uk-biobank-s-new-manchester-headquarters 2026-08-01T16:10:55+00:00 hourly 0.9 https://trial.medpath.com/news/moldova-receives-50310-doses-of-pfizer-biontech-covid-19-vaccine-through-covax-platform 2026-08-01T16:10:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moldova-receives-50310-doses-of-pfizer-biontech-covid-19-vaccine-through-covax-platform 2026-08-01T16:10:37+00:00 hourly 0.9 https://trial.medpath.com/news/jammu-and-kashmir-emerges-as-north-india-s-biotechnology-hub-with-operationalisation-of-industrial-biotech-park-in-kathua 2026-08-01T16:10:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jammu-and-kashmir-emerges-as-north-india-s-biotechnology-hub-with-operationalisation-of-industrial-biotech-park-in-kathua 2026-08-01T16:10:14+00:00 hourly 0.9 https://trial.medpath.com/news/thailand-s-competitive-strength-lies-in-its-ability-to-consistently-deliver-high-quality-clinical-trials-at-scale 2026-08-01T16:09:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thailand-s-competitive-strength-lies-in-its-ability-to-consistently-deliver-high-quality-clinical-trials-at-scale 2026-08-01T16:09:35+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-delfi-blood-test-validated-for-liver-cancer-detection-across-diverse-populations 2026-08-01T15:08:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-delfi-blood-test-validated-for-liver-cancer-detection-across-diverse-populations 2026-08-01T15:08:50+00:00 hourly 0.9 https://trial.medpath.com/news/trispecific-antibodies-the-next-frontier-in-immunotherapy-gains-momentum-with-big-pharma-investments 2026-08-01T11:07:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trispecific-antibodies-the-next-frontier-in-immunotherapy-gains-momentum-with-big-pharma-investments 2026-08-01T11:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/epigenetic-clocks-reveal-which-anti-aging-interventions-actually-slow-biological-aging 2026-08-01T11:07:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epigenetic-clocks-reveal-which-anti-aging-interventions-actually-slow-biological-aging 2026-08-01T11:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/columbia-researchers-pinpoint-endosome-dysfunction-as-the-earliest-driver-of-alzheimer-s-disease 2026-08-01T11:07:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/columbia-researchers-pinpoint-endosome-dysfunction-as-the-earliest-driver-of-alzheimer-s-disease 2026-08-01T11:07:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-cancer-drug-approvals-show-troubling-shift-toward-surrogate-endpoints-and-single-arm-trials-over-two-decades 2026-08-01T10:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-cancer-drug-approvals-show-troubling-shift-toward-surrogate-endpoints-and-single-arm-trials-over-two-decades 2026-08-01T10:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/nearly-90-of-biomedical-papers-show-signs-of-ai-assisted-writing-study-finds 2026-08-01T10:07:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nearly-90-of-biomedical-papers-show-signs-of-ai-assisted-writing-study-finds 2026-08-01T10:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/kaigene-licenses-next-generation-fcrn-inhibitor-kg006-to-taisho-for-japan-in-deal-worth-up-to-351-million 2026-08-01T09:08:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kaigene-licenses-next-generation-fcrn-inhibitor-kg006-to-taisho-for-japan-in-deal-worth-up-to-351-million 2026-08-01T09:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/medicare-pay-cut-sparks-specialty-battle-over-skin-cancer-care 2026-08-01T08:08:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicare-pay-cut-sparks-specialty-battle-over-skin-cancer-care 2026-08-01T08:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/protein-and-amino-acid-restriction-may-unlock-new-pathways-for-healthy-aging-major-review-finds 2026-08-01T03:08:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protein-and-amino-acid-restriction-may-unlock-new-pathways-for-healthy-aging-major-review-finds 2026-08-01T03:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/ohio-issues-public-safety-warning-on-orphine-analogs-and-veterinary-sedatives-in-drug-supply 2026-08-01T02:08:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ohio-issues-public-safety-warning-on-orphine-analogs-and-veterinary-sedatives-in-drug-supply 2026-08-01T02:08:54+00:00 hourly 0.9 https://trial.medpath.com/news/australian-researcher-advances-personalised-immunotherapy-with-melanoma-prediction-tool-and-600-patient-cohort 2026-08-01T00:07:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australian-researcher-advances-personalised-immunotherapy-with-melanoma-prediction-tool-and-600-patient-cohort 2026-08-01T00:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/bd-issues-nationwide-recall-of-intraosseous-vascular-access-needle-sets-linked-to-four-deaths 2026-08-01T00:07:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bd-issues-nationwide-recall-of-intraosseous-vascular-access-needle-sets-linked-to-four-deaths 2026-08-01T00:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/urinary-metal-mixtures-linked-to-29-higher-cardiovascular-disease-risk-and-66-higher-mortality-in-largest-prospective-study-to-date 2026-08-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/urinary-metal-mixtures-linked-to-29-higher-cardiovascular-disease-risk-and-66-higher-mortality-in-largest-prospective-study-to-date 2026-08-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/mantis-biotech-s-parva-uses-ai-to-rethink-how-women-s-cognitive-health-is-diagnosed 2026-07-31T23:08:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mantis-biotech-s-parva-uses-ai-to-rethink-how-women-s-cognitive-health-is-diagnosed 2026-07-31T23:08:48+00:00 hourly 0.9 https://trial.medpath.com/news/sheba-medical-center-bridges-europe-s-til-therapy-gap-for-advanced-melanoma-patients 2026-07-31T23:08:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sheba-medical-center-bridges-europe-s-til-therapy-gap-for-advanced-melanoma-patients 2026-07-31T23:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/global-bioprocessing-equipment-market-to-reach-152-2-billion-by-2035-driven-by-biologics-boom-and-single-use-technology-adoption 2026-07-31T23:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-bioprocessing-equipment-market-to-reach-152-2-billion-by-2035-driven-by-biologics-boom-and-single-use-technology-adoption 2026-07-31T23:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-alumni-medicinal-chemists-receive-2026-acs-early-career-investigator-awards 2026-07-31T22:14:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucla-alumni-medicinal-chemists-receive-2026-acs-early-career-investigator-awards 2026-07-31T22:14:01+00:00 hourly 0.9 https://trial.medpath.com/news/three-probable-tularemia-cases-reported-in-suffolk-county-raising-tick-borne-disease-concerns 2026-07-31T22:13:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/three-probable-tularemia-cases-reported-in-suffolk-county-raising-tick-borne-disease-concerns 2026-07-31T22:13:52+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-ziltivekimab-fails-zeus-phase-3-trial-triggering-largest-single-day-stock-drop-since-february-2026 2026-07-31T22:12:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-s-ziltivekimab-fails-zeus-phase-3-trial-triggering-largest-single-day-stock-drop-since-february-2026 2026-07-31T22:12:56+00:00 hourly 0.9 https://trial.medpath.com/news/protein-restriction-may-slow-aging-and-extend-lifespan-comprehensive-review-of-350-papers-suggests 2026-07-31T21:09:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protein-restriction-may-slow-aging-and-extend-lifespan-comprehensive-review-of-350-papers-suggests 2026-07-31T21:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/hct-asct-confirmed-as-standard-of-care-consolidation-for-primary-cns-lymphoma-in-landmark-phase-iii-trial 2026-07-31T20:12:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hct-asct-confirmed-as-standard-of-care-consolidation-for-primary-cns-lymphoma-in-landmark-phase-iii-trial 2026-07-31T20:12:22+00:00 hourly 0.9 https://trial.medpath.com/news/shanghai-industry-association-issues-first-ever-technical-standard-for-plant-derived-exosome-like-nanovesicles 2026-07-31T20:11:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shanghai-industry-association-issues-first-ever-technical-standard-for-plant-derived-exosome-like-nanovesicles 2026-07-31T20:11:09+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-builds-mrna-lnp-and-adc-capabilities-to-advance-oncology-and-virology-pipelines 2026-07-31T20:10:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-builds-mrna-lnp-and-adc-capabilities-to-advance-oncology-and-virology-pipelines 2026-07-31T20:10:58+00:00 hourly 0.9 https://trial.medpath.com/news/prof-fabrice-barlesi-reappointed-as-director-general-of-gustave-roussy-for-a-second-five-year-term 2026-07-31T19:11:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prof-fabrice-barlesi-reappointed-as-director-general-of-gustave-roussy-for-a-second-five-year-term 2026-07-31T19:11:56+00:00 hourly 0.9 https://trial.medpath.com/news/ketamine-induces-sex-specific-neuroplasticity-through-microglial-activation-in-female-mice 2026-07-31T19:11:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ketamine-induces-sex-specific-neuroplasticity-through-microglial-activation-in-female-mice 2026-07-31T19:11:42+00:00 hourly 0.9 https://trial.medpath.com/news/cu-anschutz-clinical-research-recruitment-program-doubles-study-inquiries-through-website-redesign 2026-07-31T19:11:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cu-anschutz-clinical-research-recruitment-program-doubles-study-inquiries-through-website-redesign 2026-07-31T19:11:04+00:00 hourly 0.9 https://trial.medpath.com/news/nippon-shinyaku-exercises-30-million-u-s-commercialization-option-for-ab2-bio-s-tadekinig-alfa-in-ultra-rare-pediatric-hyperinflammatory-syndrome 2026-07-31T17:11:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nippon-shinyaku-exercises-30-million-u-s-commercialization-option-for-ab2-bio-s-tadekinig-alfa-in-ultra-rare-pediatric-hyperinflammatory-syndrome 2026-07-31T17:11:20+00:00 hourly 0.9 https://trial.medpath.com/news/whx-osaka-positions-osaka-as-a-global-hub-for-healthy-longevity-and-life-sciences-innovation 2026-07-31T17:10:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/whx-osaka-positions-osaka-as-a-global-hub-for-healthy-longevity-and-life-sciences-innovation 2026-07-31T17:10:32+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-clues-emerge-for-car-t-toxicity-risk-opening-path-to-safer-cell-therapies 2026-07-31T17:10:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genetic-clues-emerge-for-car-t-toxicity-risk-opening-path-to-safer-cell-therapies 2026-07-31T17:10:02+00:00 hourly 0.9 https://trial.medpath.com/news/novel-ai-model-predicts-tp53-mutations-and-survival-across-32-cancer-types-from-routine-pathology-slides 2026-07-31T17:09:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-ai-model-predicts-tp53-mutations-and-survival-across-32-cancer-types-from-routine-pathology-slides 2026-07-31T17:09:37+00:00 hourly 0.9 https://trial.medpath.com/news/paclitaxel-coated-balloon-matches-rapamycin-eluting-stent-in-de-novo-small-vessel-coronary-disease 2026-07-31T16:09:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paclitaxel-coated-balloon-matches-rapamycin-eluting-stent-in-de-novo-small-vessel-coronary-disease 2026-07-31T16:09:21+00:00 hourly 0.9 https://trial.medpath.com/news/contineum-s-jnj-5120-pipe-307-misses-primary-endpoint-in-phase-2-moonlight-1-depression-trial 2026-07-31T15:08:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/contineum-s-jnj-5120-pipe-307-misses-primary-endpoint-in-phase-2-moonlight-1-depression-trial 2026-07-31T15:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/palvella-therapeutics-reports-q2-loss-of-21-9-million-missing-wall-street-estimates 2026-07-31T14:09:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/palvella-therapeutics-reports-q2-loss-of-21-9-million-missing-wall-street-estimates 2026-07-31T14:09:27+00:00 hourly 0.9 https://trial.medpath.com/news/large-us-echo-cohort-study-finds-no-overall-link-between-prenatal-water-fluoride-and-children-s-behavior 2026-07-31T14:09:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-us-echo-cohort-study-finds-no-overall-link-between-prenatal-water-fluoride-and-children-s-behavior 2026-07-31T14:09:04+00:00 hourly 0.9 https://trial.medpath.com/news/create-medicines-acquires-monash-s-8-fold-lnp-targeting-technology-to-solve-in-vivo-car-t-s-liver-delivery-problem 2026-07-31T14:08:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/create-medicines-acquires-monash-s-8-fold-lnp-targeting-technology-to-solve-in-vivo-car-t-s-liver-delivery-problem 2026-07-31T14:08:54+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-ziltivekimab-fails-phase-3-zeus-trial-missing-primary-mace-endpoint-in-cardiovascular-disease 2026-07-31T14:08:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-s-ziltivekimab-fails-phase-3-zeus-trial-missing-primary-mace-endpoint-in-cardiovascular-disease 2026-07-31T14:08:52+00:00 hourly 0.9 https://trial.medpath.com/news/multimodal-ai-in-surgical-oncology-shows-promise-but-lacks-prospective-evidence-review-finds 2026-07-31T13:08:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multimodal-ai-in-surgical-oncology-shows-promise-but-lacks-prospective-evidence-review-finds 2026-07-31T13:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-to-launch-integrated-digital-drug-regulatory-platform-within-18-months-piloting-ai-to-slash-processing-times 2026-07-31T13:08:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-to-launch-integrated-digital-drug-regulatory-platform-within-18-months-piloting-ai-to-slash-processing-times 2026-07-31T13:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/ractigen-therapeutics-secures-u-s-fda-ind-clearance-for-first-in-class-sarna-therapy-rag-1c-targeting-proliferative-vitreoretinopathy 2026-07-31T12:09:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ractigen-therapeutics-secures-u-s-fda-ind-clearance-for-first-in-class-sarna-therapy-rag-1c-targeting-proliferative-vitreoretinopathy 2026-07-31T12:09:06+00:00 hourly 0.9 https://trial.medpath.com/news/smart-materials-and-devices-for-stimuli-responsive-drug-delivery-advancing-precision-therapeutics 2026-07-31T12:08:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smart-materials-and-devices-for-stimuli-responsive-drug-delivery-advancing-precision-therapeutics 2026-07-31T12:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/vector-centre-advances-mrna-vaccine-pipeline-for-hiv-monkeypox-and-tick-borne-encephalitis 2026-07-31T11:09:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vector-centre-advances-mrna-vaccine-pipeline-for-hiv-monkeypox-and-tick-borne-encephalitis 2026-07-31T11:09:06+00:00 hourly 0.9 https://trial.medpath.com/news/impact-therapeutics-licenses-parp-inhibitor-senaparib-to-pharmanovia-in-deal-worth-up-to-eur423-5-million 2026-07-31T10:10:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/impact-therapeutics-licenses-parp-inhibitor-senaparib-to-pharmanovia-in-deal-worth-up-to-eur423-5-million 2026-07-31T10:10:18+00:00 hourly 0.9 https://trial.medpath.com/news/dual-cd19-cd70-car-t-therapy-shows-superior-lymphoma-control-in-preclinical-models-cd70-identified-as-relapse-biomarker 2026-07-31T10:10:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-cd19-cd70-car-t-therapy-shows-superior-lymphoma-control-in-preclinical-models-cd70-identified-as-relapse-biomarker 2026-07-31T10:10:14+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-s-oncology-pipeline-surge-firefly-bio-acquisition-sail-biomedicines-car-t-deal-and-ottava-robotic-system-fda-authorization 2026-07-31T09:10:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-s-oncology-pipeline-surge-firefly-bio-acquisition-sail-biomedicines-car-t-deal-and-ottava-robotic-system-fda-authorization 2026-07-31T09:10:47+00:00 hourly 0.9 https://trial.medpath.com/news/uams-acquires-proton-center-of-arkansas-securing-long-term-access-to-advanced-cancer-therapy 2026-07-31T08:10:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uams-acquires-proton-center-of-arkansas-securing-long-term-access-to-advanced-cancer-therapy 2026-07-31T08:10:56+00:00 hourly 0.9 https://trial.medpath.com/news/precision-medicine-advances-in-pediatric-sarcoma-ntrk-targeted-therapy-and-multimodal-care-transform-outcomes 2026-07-31T06:12:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-medicine-advances-in-pediatric-sarcoma-ntrk-targeted-therapy-and-multimodal-care-transform-outcomes 2026-07-31T06:12:04+00:00 hourly 0.9 https://trial.medpath.com/news/kansas-hospitals-expand-access-to-fda-approved-anti-amyloid-infusion-therapies-for-early-alzheimer-s-disease 2026-07-31T06:12:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kansas-hospitals-expand-access-to-fda-approved-anti-amyloid-infusion-therapies-for-early-alzheimer-s-disease 2026-07-31T06:12:01+00:00 hourly 0.9 https://trial.medpath.com/news/mediwound-advances-escharex-phase-iii-valu-trial-as-updated-u-s-market-assessment-tops-1-billion 2026-07-31T06:11:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mediwound-advances-escharex-phase-iii-valu-trial-as-updated-u-s-market-assessment-tops-1-billion 2026-07-31T06:11:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-unveils-fy-2027-user-fee-rates-pdufa-revenue-target-rises-6-mdufa-jumps-14 2026-07-31T06:11:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-unveils-fy-2027-user-fee-rates-pdufa-revenue-target-rises-6-mdufa-jumps-14 2026-07-31T06:11:49+00:00 hourly 0.9 https://trial.medpath.com/news/ensifentrine-improves-lung-function-in-chinese-patients-with-copd-enhance-china-study 2026-07-31T06:11:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ensifentrine-improves-lung-function-in-chinese-patients-with-copd-enhance-china-study 2026-07-31T06:11:20+00:00 hourly 0.9 https://trial.medpath.com/news/apnimed-closes-upsized-220-8-million-ipo-to-advance-oral-therapy-for-obstructive-sleep-apnea 2026-07-31T03:20:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apnimed-closes-upsized-220-8-million-ipo-to-advance-oral-therapy-for-obstructive-sleep-apnea 2026-07-31T03:20:20+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-de-novo-authorization-to-caristo-s-cari-heart-first-ai-powered-coronary-inflammation-quantification-technology 2026-07-31T03:20:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-de-novo-authorization-to-caristo-s-cari-heart-first-ai-powered-coronary-inflammation-quantification-technology 2026-07-31T03:20:19+00:00 hourly 0.9 https://trial.medpath.com/news/squires-erases-ptab-ax-of-dermatology-ip-upheld-at-itc 2026-07-31T03:19:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/squires-erases-ptab-ax-of-dermatology-ip-upheld-at-itc 2026-07-31T03:19:50+00:00 hourly 0.9 https://trial.medpath.com/news/fructose-identified-as-surprise-driver-of-ovarian-cancer-metastasis-after-chemotherapy 2026-07-31T03:19:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fructose-identified-as-surprise-driver-of-ovarian-cancer-metastasis-after-chemotherapy 2026-07-31T03:19:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-cleared-single-port-robotic-nipple-sparing-mastectomy-performed-at-community-hospital-for-the-first-time 2026-07-31T03:18:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-cleared-single-port-robotic-nipple-sparing-mastectomy-performed-at-community-hospital-for-the-first-time 2026-07-31T03:18:22+00:00 hourly 0.9 https://trial.medpath.com/news/federal-medical-scientists-turn-to-llms-as-research-co-pilots-across-fda-nci-and-argonne 2026-07-31T03:15:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-medical-scientists-turn-to-llms-as-research-co-pilots-across-fda-nci-and-argonne 2026-07-31T03:15:31+00:00 hourly 0.9 https://trial.medpath.com/news/biopharmaceutical-pat-market-projected-to-reach-4-32-billion-by-2031-driven-by-vaccine-manufacturing-and-asia-pacific-expansion 2026-07-31T03:14:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biopharmaceutical-pat-market-projected-to-reach-4-32-billion-by-2031-driven-by-vaccine-manufacturing-and-asia-pacific-expansion 2026-07-31T03:14:39+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-uncover-two-mysterious-ghost-ancestors-hiding-in-modern-human-dna 2026-07-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-uncover-two-mysterious-ghost-ancestors-hiding-in-modern-human-dna 2026-07-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/anti-virulence-agents-targeting-bacterial-quorum-sensing-emerge-as-resistance-sparing-strategy-in-post-antibiotic-era 2026-07-30T22:28:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anti-virulence-agents-targeting-bacterial-quorum-sensing-emerge-as-resistance-sparing-strategy-in-post-antibiotic-era 2026-07-30T22:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/prothena-to-report-second-quarter-2026-financial-results-on-august-6 2026-07-30T22:15:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prothena-to-report-second-quarter-2026-financial-results-on-august-6 2026-07-30T22:15:42+00:00 hourly 0.9 https://trial.medpath.com/news/calls-mount-for-reform-of-south-korean-dental-schools-clinical-training-patient-recruitment-system 2026-07-30T22:15:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/calls-mount-for-reform-of-south-korean-dental-schools-clinical-training-patient-recruitment-system 2026-07-30T22:15:08+00:00 hourly 0.9 https://trial.medpath.com/news/measles-rna-detected-in-anchorage-wastewater-prompting-vaccination-warnings-amid-low-immunization-rates 2026-07-30T22:15:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/measles-rna-detected-in-anchorage-wastewater-prompting-vaccination-warnings-amid-low-immunization-rates 2026-07-30T22:15:01+00:00 hourly 0.9 https://trial.medpath.com/news/hokkaido-university-scientists-develop-e-mito-a-surface-engineered-mitochondrial-delivery-system-for-organelle-based-therapeutics 2026-07-30T22:14:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hokkaido-university-scientists-develop-e-mito-a-surface-engineered-mitochondrial-delivery-system-for-organelle-based-therapeutics 2026-07-30T22:14:11+00:00 hourly 0.9 https://trial.medpath.com/news/singapore-clinical-trials-symposium-2026-asia-charts-path-to-become-global-epicenter-for-clinical-research 2026-07-30T22:13:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/singapore-clinical-trials-symposium-2026-asia-charts-path-to-become-global-epicenter-for-clinical-research 2026-07-30T22:13:16+00:00 hourly 0.9 https://trial.medpath.com/news/federal-appeals-court-revives-maximum-strength-claims-in-oral-phenylephrine-decongestant-false-advertising-litigation 2026-07-30T22:12:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-appeals-court-revives-maximum-strength-claims-in-oral-phenylephrine-decongestant-false-advertising-litigation 2026-07-30T22:12:30+00:00 hourly 0.9 https://trial.medpath.com/news/pharmaceutical-r-d-workforce-trends-phrma-and-usamriid-employment-data-reveal-shifting-global-footprints-in-2026 2026-07-30T22:11:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmaceutical-r-d-workforce-trends-phrma-and-usamriid-employment-data-reveal-shifting-global-footprints-in-2026 2026-07-30T22:11:20+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-restore-lost-protein-bmp3-to-reverse-pulmonary-arterial-hypertension-in-preclinical-models 2026-07-30T21:08:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-restore-lost-protein-bmp3-to-reverse-pulmonary-arterial-hypertension-in-preclinical-models 2026-07-30T21:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/virginia-catalyst-awards-2-4-million-to-advance-surgical-hydrogel-trauma-resuscitation-drug-and-ai-enabled-fracture-healing-device-toward-human-trials 2026-07-30T21:08:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/virginia-catalyst-awards-2-4-million-to-advance-surgical-hydrogel-trauma-resuscitation-drug-and-ai-enabled-fracture-healing-device-toward-human-trials 2026-07-30T21:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/early-remdesivir-tied-to-reduced-graft-loss-and-cardiovascular-events-in-kidney-transplant-recipients-with-acute-covid-19 2026-07-30T21:08:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/early-remdesivir-tied-to-reduced-graft-loss-and-cardiovascular-events-in-kidney-transplant-recipients-with-acute-covid-19 2026-07-30T21:08:06+00:00 hourly 0.9 https://trial.medpath.com/news/meitheal-pharmaceuticals-announces-fda-approval-of-garzulystm-insulin-aspart-fsan-a-biosimilar-to-novolog 2026-07-30T21:08:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meitheal-pharmaceuticals-announces-fda-approval-of-garzulystm-insulin-aspart-fsan-a-biosimilar-to-novolog 2026-07-30T21:08:05+00:00 hourly 0.9 https://trial.medpath.com/news/nsf-awards-uc-san-diego-18-million-to-establish-quantum-materials-research-center 2026-07-30T20:10:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nsf-awards-uc-san-diego-18-million-to-establish-quantum-materials-research-center 2026-07-30T20:10:06+00:00 hourly 0.9 https://trial.medpath.com/news/opportunistic-salpingectomy-reduces-ovarian-cancer-risk-by-78-experts-call-it-a-no-brainer 2026-07-30T19:10:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/opportunistic-salpingectomy-reduces-ovarian-cancer-risk-by-78-experts-call-it-a-no-brainer 2026-07-30T19:10:51+00:00 hourly 0.9 https://trial.medpath.com/news/recovryai-completes-patient-phase-of-pivotal-trial-for-ai-powered-postoperative-virtual-care-assistant 2026-07-30T18:34:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recovryai-completes-patient-phase-of-pivotal-trial-for-ai-powered-postoperative-virtual-care-assistant 2026-07-30T18:34:59+00:00 hourly 0.9 https://trial.medpath.com/news/openabe-gene-editor-achieves-up-to-36-fold-efficiency-gain-overcoming-ai-designed-editor-limitations 2026-07-30T18:34:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/openabe-gene-editor-achieves-up-to-36-fold-efficiency-gain-overcoming-ai-designed-editor-limitations 2026-07-30T18:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/nano-flow-cytometry-advances-single-particle-characterization-of-targeted-lipid-nanoparticles-for-extrahepatic-delivery 2026-07-30T18:34:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nano-flow-cytometry-advances-single-particle-characterization-of-targeted-lipid-nanoparticles-for-extrahepatic-delivery 2026-07-30T18:34:38+00:00 hourly 0.9 https://trial.medpath.com/news/tvardi-therapeutics-selects-ulcerative-colitis-as-initial-indication-for-stat3-inhibitor-tti-109-plans-2027-trial 2026-07-30T18:34:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tvardi-therapeutics-selects-ulcerative-colitis-as-initial-indication-for-stat3-inhibitor-tti-109-plans-2027-trial 2026-07-30T18:34:34+00:00 hourly 0.9 https://trial.medpath.com/news/probiotic-derived-metabolite-10-hsa-repairs-hiv-gut-damage-and-boosts-art-response-in-preclinical-model 2026-07-30T18:34:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/probiotic-derived-metabolite-10-hsa-repairs-hiv-gut-damage-and-boosts-art-response-in-preclinical-model 2026-07-30T18:34:33+00:00 hourly 0.9 https://trial.medpath.com/news/diamedica-s-dm199-rinvecalinase-alfa-advances-in-preeclampsia-and-stroke-phase-2-data-regulatory-milestones-and-market-outlook 2026-07-30T16:09:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diamedica-s-dm199-rinvecalinase-alfa-advances-in-preeclampsia-and-stroke-phase-2-data-regulatory-milestones-and-market-outlook 2026-07-30T16:09:43+00:00 hourly 0.9 https://trial.medpath.com/news/new-study-investigates-why-female-patients-experience-more-severe-oral-mucositis-after-head-and-neck-cancer-radiation 2026-07-30T16:09:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-study-investigates-why-female-patients-experience-more-severe-oral-mucositis-after-head-and-neck-cancer-radiation 2026-07-30T16:09:23+00:00 hourly 0.9 https://trial.medpath.com/news/lencabo-trial-reveals-catabolic-trade-off-for-lenvatinib-everolimus-in-metastatic-ccrcc 2026-07-30T16:09:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lencabo-trial-reveals-catabolic-trade-off-for-lenvatinib-everolimus-in-metastatic-ccrcc 2026-07-30T16:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/mercantile-life-science-ventures-and-big-idea-ventures-invest-in-maia-fertility-to-advance-ferizymetm-platform 2026-07-30T16:09:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mercantile-life-science-ventures-and-big-idea-ventures-invest-in-maia-fertility-to-advance-ferizymetm-platform 2026-07-30T16:09:06+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-mmi-to-expand-enrollment-in-pioneering-robotic-microsurgery-trial-for-alzheimer-s-disease 2026-07-30T16:08:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-mmi-to-expand-enrollment-in-pioneering-robotic-microsurgery-trial-for-alzheimer-s-disease 2026-07-30T16:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/ai-protein-design-market-to-reach-13-70-billion-by-2035-as-generative-models-reshape-drug-discovery 2026-07-30T16:08:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-protein-design-market-to-reach-13-70-billion-by-2035-as-generative-models-reshape-drug-discovery 2026-07-30T16:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/orexin-receptor-agonists-herald-a-new-era-for-narcolepsy-type-1-treatment 2026-07-30T16:07:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orexin-receptor-agonists-herald-a-new-era-for-narcolepsy-type-1-treatment 2026-07-30T16:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/magic-molecule-launches-fda-cleared-hypochlorous-acid-skin-spray-in-more-than-4500-walmart-stores 2026-07-30T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/magic-molecule-launches-fda-cleared-hypochlorous-acid-skin-spray-in-more-than-4500-walmart-stores 2026-07-30T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/chandigarh-university-biotech-and-pharmacy-students-secure-178-placements-with-leading-pharma-companies 2026-07-30T14:18:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chandigarh-university-biotech-and-pharmacy-students-secure-178-placements-with-leading-pharma-companies 2026-07-30T14:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/hong-kong-establishes-first-pic-s-gmp-certified-stem-cell-manufacturing-facility-advancing-cell-and-gene-therapy-ecosystem 2026-07-30T14:18:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hong-kong-establishes-first-pic-s-gmp-certified-stem-cell-manufacturing-facility-advancing-cell-and-gene-therapy-ecosystem 2026-07-30T14:18:47+00:00 hourly 0.9 https://trial.medpath.com/news/nippon-shinyaku-exercises-option-for-ab2-bio-s-tadekinig-alfa-securing-u-s-commercialization-rights-for-rare-autoinflammatory-diseases 2026-07-30T14:18:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nippon-shinyaku-exercises-option-for-ab2-bio-s-tadekinig-alfa-securing-u-s-commercialization-rights-for-rare-autoinflammatory-diseases 2026-07-30T14:18:38+00:00 hourly 0.9 https://trial.medpath.com/news/insilico-medicine-launches-industry-s-first-drug-discovery-and-development-benchmark-as-a-service-to-validate-ai-models-against-real-world-pharmaceutical-data 2026-07-30T14:17:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insilico-medicine-launches-industry-s-first-drug-discovery-and-development-benchmark-as-a-service-to-validate-ai-models-against-real-world-pharmaceutical-data 2026-07-30T14:17:49+00:00 hourly 0.9 https://trial.medpath.com/news/direct-to-patient-models-reshape-pharma-s-commercial-strategy-as-nine-major-companies-launch-branded-drug-channels 2026-07-30T13:07:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/direct-to-patient-models-reshape-pharma-s-commercial-strategy-as-nine-major-companies-launch-branded-drug-channels 2026-07-30T13:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/sustained-heatwaves-driving-increased-risk-of-infectious-diseases-across-europe-ecdc-warns 2026-07-30T12:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sustained-heatwaves-driving-increased-risk-of-infectious-diseases-across-europe-ecdc-warns 2026-07-30T12:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/global-botulinum-toxin-market-poised-to-reach-29-billion-by-2035-driven-by-aesthetic-democratization-and-expanding-therapeutic-indications 2026-07-30T11:08:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-botulinum-toxin-market-poised-to-reach-29-billion-by-2035-driven-by-aesthetic-democratization-and-expanding-therapeutic-indications 2026-07-30T11:08:51+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-and-relation-therapeutics-sign-up-to-110-million-ai-drug-discovery-deal 2026-07-30T11:08:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-and-relation-therapeutics-sign-up-to-110-million-ai-drug-discovery-deal 2026-07-30T11:08:16+00:00 hourly 0.9 https://trial.medpath.com/news/actimed-therapeutics-appoints-dr-anders-ullman-to-board-as-it-advances-pipeline-in-cancer-cachexia-and-muscle-wasting 2026-07-30T11:08:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actimed-therapeutics-appoints-dr-anders-ullman-to-board-as-it-advances-pipeline-in-cancer-cachexia-and-muscle-wasting 2026-07-30T11:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/fierce-pharma-week-europe-launches-in-basel-for-2027-targeting-cross-functional-pharma-leadership 2026-07-30T10:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fierce-pharma-week-europe-launches-in-basel-for-2027-targeting-cross-functional-pharma-leadership 2026-07-30T10:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-biontech-s-xfg-adapted-covid-19-vaccine-wins-fda-approval-for-at-risk-adults 2026-07-30T10:08:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-biontech-s-xfg-adapted-covid-19-vaccine-wins-fda-approval-for-at-risk-adults 2026-07-30T10:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/nara-smith-credits-couples-therapy-for-navigating-daughter-s-cancer-journey 2026-07-30T10:08:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nara-smith-credits-couples-therapy-for-navigating-daughter-s-cancer-journey 2026-07-30T10:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/pregnancy-after-car-t-cell-therapy-new-data-on-fertility-outcomes 2026-07-30T10:08:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pregnancy-after-car-t-cell-therapy-new-data-on-fertility-outcomes 2026-07-30T10:08:37+00:00 hourly 0.9 https://trial.medpath.com/news/pulse-biosciences-surpasses-enrollment-midpoint-in-nanopulse-af-pivotal-trial-for-nanosecond-pulsed-field-ablation 2026-07-30T10:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pulse-biosciences-surpasses-enrollment-midpoint-in-nanopulse-af-pivotal-trial-for-nanosecond-pulsed-field-ablation 2026-07-30T10:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/shield-therapeutics-reports-30-4m-h1-2026-revenue-advances-accrufer-r-into-phase-ii-pah-trial-in-japan 2026-07-30T09:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shield-therapeutics-reports-30-4m-h1-2026-revenue-advances-accrufer-r-into-phase-ii-pah-trial-in-japan 2026-07-30T09:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/the-systemic-bottleneck-why-biopharma-s-drug-development-crisis-is-organizational-not-scientific 2026-07-30T09:07:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-systemic-bottleneck-why-biopharma-s-drug-development-crisis-is-organizational-not-scientific 2026-07-30T09:07:09+00:00 hourly 0.9 https://trial.medpath.com/news/teclistamab-enables-kidney-transplant-in-patient-with-zero-compatibility-odds-published-in-nejm 2026-07-30T09:07:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teclistamab-enables-kidney-transplant-in-patient-with-zero-compatibility-odds-published-in-nejm 2026-07-30T09:07:06+00:00 hourly 0.9 https://trial.medpath.com/news/leadership-changes-at-novartis-india-two-directors-step-down 2026-07-30T07:09:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leadership-changes-at-novartis-india-two-directors-step-down 2026-07-30T07:09:02+00:00 hourly 0.9 https://trial.medpath.com/news/acadia-pharmaceuticals-to-present-at-canaccord-genuity-46th-annual-growth-conference 2026-07-30T07:08:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acadia-pharmaceuticals-to-present-at-canaccord-genuity-46th-annual-growth-conference 2026-07-30T07:08:56+00:00 hourly 0.9 https://trial.medpath.com/news/european-commission-authorizes-pfizer-biontech-xfg-adapted-covid-19-vaccine-for-2026-2027-season 2026-07-30T07:08:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-commission-authorizes-pfizer-biontech-xfg-adapted-covid-19-vaccine-for-2026-2027-season 2026-07-30T07:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-upgrades-2026-guidance-on-23-5-sales-growth-positive-phase-iii-readouts-and-pipeline-building-acquisitions 2026-07-30T07:07:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ipsen-upgrades-2026-guidance-on-23-5-sales-growth-positive-phase-iii-readouts-and-pipeline-building-acquisitions 2026-07-30T07:07:24+00:00 hourly 0.9 https://trial.medpath.com/news/in-bed-cycling-plus-protein-supplementation-fails-to-improve-physical-recovery-in-icu-patients-with-acute-respiratory-failure-nexis-trial-finds 2026-07-30T06:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/in-bed-cycling-plus-protein-supplementation-fails-to-improve-physical-recovery-in-icu-patients-with-acute-respiratory-failure-nexis-trial-finds 2026-07-30T06:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/isothermal-nucleic-acid-amplification-technology-market-to-reach-usd-16-7-billion-by-2034 2026-07-30T06:07:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/isothermal-nucleic-acid-amplification-technology-market-to-reach-usd-16-7-billion-by-2034 2026-07-30T06:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/beyond-air-to-sell-neuronos-stake-to-univo-in-exchange-for-equity-and-up-to-32-5-million-in-milestone-payments 2026-07-30T05:42:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beyond-air-to-sell-neuronos-stake-to-univo-in-exchange-for-equity-and-up-to-32-5-million-in-milestone-payments 2026-07-30T05:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/jeil-pharmaceutical-s-dual-sglt-1-2-inhibitor-jp-2266-shows-significant-hba1c-reduction-in-phase-2-diabetes-trial 2026-07-30T02:10:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jeil-pharmaceutical-s-dual-sglt-1-2-inhibitor-jp-2266-shows-significant-hba1c-reduction-in-phase-2-diabetes-trial 2026-07-30T02:10:33+00:00 hourly 0.9 https://trial.medpath.com/news/new-ai-powered-home-test-uses-thigh-length-to-detect-type-2-diabetes-and-prediabetes 2026-07-30T02:09:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-ai-powered-home-test-uses-thigh-length-to-detect-type-2-diabetes-and-prediabetes 2026-07-30T02:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/fauci-invokes-fifth-amendment-over-100-times-in-contentious-senate-hearing-paul-seeks-contempt-charges 2026-07-30T02:08:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fauci-invokes-fifth-amendment-over-100-times-in-contentious-senate-hearing-paul-seeks-contempt-charges 2026-07-30T02:08:44+00:00 hourly 0.9 https://trial.medpath.com/news/world-hepatitis-day-research-topics-highlight-gaps-in-diagnosis-treatment-access-and-pediatric-elimination-of-viral-hepatitis 2026-07-30T02:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-hepatitis-day-research-topics-highlight-gaps-in-diagnosis-treatment-access-and-pediatric-elimination-of-viral-hepatitis 2026-07-30T02:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/adjuvia-therapeutics-raises-8-million-seed-round-to-advance-mitochondrial-therapy-ati-105-toward-clinical-trials 2026-07-30T01:06:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adjuvia-therapeutics-raises-8-million-seed-round-to-advance-mitochondrial-therapy-ati-105-toward-clinical-trials 2026-07-30T01:06:14+00:00 hourly 0.9 https://trial.medpath.com/news/purdue-veterinary-conference-2026-to-spotlight-one-health-professional-wellness-and-human-animal-bond-research 2026-07-30T01:06:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/purdue-veterinary-conference-2026-to-spotlight-one-health-professional-wellness-and-human-animal-bond-research 2026-07-30T01:06:09+00:00 hourly 0.9 https://trial.medpath.com/news/boston-researchers-advance-toward-diagnosing-cte-in-living-patients-enlisting-former-nfl-quarterback-matt-hasselbeck 2026-07-30T00:53:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boston-researchers-advance-toward-diagnosing-cte-in-living-patients-enlisting-former-nfl-quarterback-matt-hasselbeck 2026-07-30T00:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/latigo-biotherapeutics-posts-positive-phase-2-data-for-non-opioid-pain-drug-challenging-vertex-s-market-position 2026-07-30T00:08:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/latigo-biotherapeutics-posts-positive-phase-2-data-for-non-opioid-pain-drug-challenging-vertex-s-market-position 2026-07-30T00:08:36+00:00 hourly 0.9 https://trial.medpath.com/news/cryopreserved-umbilical-cord-allografts-show-pain-reduction-in-cervical-paraspinal-muscle-degeneration-31-patient-study 2026-07-30T00:08:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cryopreserved-umbilical-cord-allografts-show-pain-reduction-in-cervical-paraspinal-muscle-degeneration-31-patient-study 2026-07-30T00:08:12+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-weight-loss-medications-expert-perspectives-on-efficacy-candidates-and-long-term-weight-maintenance 2026-07-30T00:08:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-weight-loss-medications-expert-perspectives-on-efficacy-candidates-and-long-term-weight-maintenance 2026-07-30T00:08:08+00:00 hourly 0.9 https://trial.medpath.com/news/manifest-io-launches-landmark-uk-wide-prospective-study-to-unravel-immunotherapy-response-and-toxicity 2026-07-30T00:07:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/manifest-io-launches-landmark-uk-wide-prospective-study-to-unravel-immunotherapy-response-and-toxicity 2026-07-30T00:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/uc-san-diego-secures-nearly-1-8-billion-in-fy26-research-awards-amid-shifting-funding-landscape 2026-07-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-san-diego-secures-nearly-1-8-billion-in-fy26-research-awards-amid-shifting-funding-landscape 2026-07-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cd27-cd39-car-t-cell-count-predicts-response-at-low-doses-study-finds 2026-07-29T23:08:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cd27-cd39-car-t-cell-count-predicts-response-at-low-doses-study-finds 2026-07-29T23:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/rpg-life-sciences-carves-out-api-business-secures-243-crore-pe-backing-to-build-integrated-pharma-platform 2026-07-29T23:07:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rpg-life-sciences-carves-out-api-business-secures-243-crore-pe-backing-to-build-integrated-pharma-platform 2026-07-29T23:07:53+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-choice-awards-2026-announced-at-adlm-thermo-fisher-mindray-siemens-healthineers-and-danaher-among-winners 2026-07-29T22:08:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-choice-awards-2026-announced-at-adlm-thermo-fisher-mindray-siemens-healthineers-and-danaher-among-winners 2026-07-29T22:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/par-health-launches-sugammadex-prefilled-syringe-to-streamline-neuromuscular-blockade-reversal-in-hospitals 2026-07-29T21:08:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/par-health-launches-sugammadex-prefilled-syringe-to-streamline-neuromuscular-blockade-reversal-in-hospitals 2026-07-29T21:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-turn-to-onlyfans-and-cryptocurrency-to-rescue-60-year-marmot-study-after-federal-funding-cuts 2026-07-29T21:08:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-turn-to-onlyfans-and-cryptocurrency-to-rescue-60-year-marmot-study-after-federal-funding-cuts 2026-07-29T21:08:29+00:00 hourly 0.9 https://trial.medpath.com/news/rose-hill-life-sciences-names-bryan-smith-scientific-advisor-as-psilocybin-pipeline-advances 2026-07-29T21:08:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rose-hill-life-sciences-names-bryan-smith-scientific-advisor-as-psilocybin-pipeline-advances 2026-07-29T21:08:29+00:00 hourly 0.9 https://trial.medpath.com/news/igf2bp3-trnau1ap-pathway-identified-as-promising-therapeutic-target-in-glioblastoma 2026-07-29T21:08:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/igf2bp3-trnau1ap-pathway-identified-as-promising-therapeutic-target-in-glioblastoma 2026-07-29T21:08:28+00:00 hourly 0.9 https://trial.medpath.com/news/elix-and-university-of-vienna-partner-to-target-undruggable-proteins-with-ai-driven-drug-discovery 2026-07-29T21:08:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elix-and-university-of-vienna-partner-to-target-undruggable-proteins-with-ai-driven-drug-discovery 2026-07-29T21:08:12+00:00 hourly 0.9 https://trial.medpath.com/news/life-sciences-students-urged-to-bridge-research-and-entrepreneurship-at-osmania-university 2026-07-29T21:08:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/life-sciences-students-urged-to-bridge-research-and-entrepreneurship-at-osmania-university 2026-07-29T21:08:08+00:00 hourly 0.9 https://trial.medpath.com/news/programmable-dna-enables-rational-design-of-protein-crystals-overturning-decades-old-assumption 2026-07-29T21:07:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/programmable-dna-enables-rational-design-of-protein-crystals-overturning-decades-old-assumption 2026-07-29T21:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-plans-to-end-medicare-part-d-subsidies-potentially-raising-drug-costs-for-millions-of-seniors 2026-07-29T20:08:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-plans-to-end-medicare-part-d-subsidies-potentially-raising-drug-costs-for-millions-of-seniors 2026-07-29T20:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/pediatric-long-covid-is-real-landmark-pecos-study-maps-lasting-effects-on-children 2026-07-29T19:36:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pediatric-long-covid-is-real-landmark-pecos-study-maps-lasting-effects-on-children 2026-07-29T19:36:38+00:00 hourly 0.9 https://trial.medpath.com/news/hemogenyx-signs-loi-with-vilnius-university-hospital-for-flt3-directed-car-t-therapy-in-aml-mds 2026-07-29T19:36:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hemogenyx-signs-loi-with-vilnius-university-hospital-for-flt3-directed-car-t-therapy-in-aml-mds 2026-07-29T19:36:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-teleflex-s-ezplaztm-freeze-dried-plasma-transforming-emergency-transfusion-care 2026-07-29T19:35:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-teleflex-s-ezplaztm-freeze-dried-plasma-transforming-emergency-transfusion-care 2026-07-29T19:35:59+00:00 hourly 0.9 https://trial.medpath.com/news/hidden-army-of-tissue-resident-memory-t-cells-defends-human-lungs-against-a-broad-range-of-pathogens 2026-07-29T19:35:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hidden-army-of-tissue-resident-memory-t-cells-defends-human-lungs-against-a-broad-range-of-pathogens 2026-07-29T19:35:48+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-issues-government-wide-ban-on-federal-funding-for-dangerous-gain-of-function-research 2026-07-29T19:34:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-issues-government-wide-ban-on-federal-funding-for-dangerous-gain-of-function-research 2026-07-29T19:34:28+00:00 hourly 0.9 https://trial.medpath.com/news/evinova-and-merck-kgaa-forge-multi-year-ai-partnership-to-transform-clinical-development 2026-07-29T19:34:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evinova-and-merck-kgaa-forge-multi-year-ai-partnership-to-transform-clinical-development 2026-07-29T19:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/nabp-to-develop-national-adverse-event-reporting-clearinghouse-for-compounded-medications 2026-07-29T19:33:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nabp-to-develop-national-adverse-event-reporting-clearinghouse-for-compounded-medications 2026-07-29T19:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/immature-nk-cells-in-donor-cord-blood-can-sabotage-car-nk-cell-therapy-md-anderson-study-reveals 2026-07-29T19:32:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immature-nk-cells-in-donor-cord-blood-can-sabotage-car-nk-cell-therapy-md-anderson-study-reveals 2026-07-29T19:32:57+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-architecture-of-cytokine-autoantibodies-and-associated-risk-of-common-diseases 2026-07-29T18:07:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genetic-architecture-of-cytokine-autoantibodies-and-associated-risk-of-common-diseases 2026-07-29T18:07:48+00:00 hourly 0.9 https://trial.medpath.com/news/raygun-duke-researchers-develop-ai-tool-that-can-shrink-and-supersize-proteins-while-preserving-function 2026-07-29T18:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/raygun-duke-researchers-develop-ai-tool-that-can-shrink-and-supersize-proteins-while-preserving-function 2026-07-29T18:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/insidetracker-unveils-source-agnostic-blood-data-connector-across-nearly-120-biomarkers 2026-07-29T18:06:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insidetracker-unveils-source-agnostic-blood-data-connector-across-nearly-120-biomarkers 2026-07-29T18:06:32+00:00 hourly 0.9 https://trial.medpath.com/news/bicara-therapeutics-strengthens-board-with-appointments-of-jeremy-bender-and-christy-oliger-as-company-advances-ficerafusp-alfa-toward-commercialization 2026-07-29T17:08:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bicara-therapeutics-strengthens-board-with-appointments-of-jeremy-bender-and-christy-oliger-as-company-advances-ficerafusp-alfa-toward-commercialization 2026-07-29T17:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/integrated-live-cell-imaging-and-cytometry-workflow-standardizes-cerebral-organoid-differentiation-for-drug-discovery 2026-07-29T17:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/integrated-live-cell-imaging-and-cytometry-workflow-standardizes-cerebral-organoid-differentiation-for-drug-discovery 2026-07-29T17:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/epo-boards-of-appeal-revokes-bms-opdivo-patent-clearing-path-for-nivolumab-biosimilars 2026-07-29T16:13:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epo-boards-of-appeal-revokes-bms-opdivo-patent-clearing-path-for-nivolumab-biosimilars 2026-07-29T16:13:47+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-receives-health-canada-approval-for-yesintek-ustekinumab-autoinjector-pen 2026-07-29T16:13:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-receives-health-canada-approval-for-yesintek-ustekinumab-autoinjector-pen 2026-07-29T16:13:12+00:00 hourly 0.9 https://trial.medpath.com/news/national-scabies-control-program-using-ivermectin-mda-drastically-reduces-disease-prevalence-in-pacific-nations 2026-07-29T16:11:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/national-scabies-control-program-using-ivermectin-mda-drastically-reduces-disease-prevalence-in-pacific-nations 2026-07-29T16:11:38+00:00 hourly 0.9 https://trial.medpath.com/news/humigent-raises-series-a-to-build-ai-intelligence-layer-for-life-sciences 2026-07-29T16:11:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/humigent-raises-series-a-to-build-ai-intelligence-layer-for-life-sciences 2026-07-29T16:11:29+00:00 hourly 0.9 https://trial.medpath.com/news/pk-med-strengthens-governance-with-gene-therapy-pioneers-ahead-of-phase-2-gout-trial 2026-07-29T16:11:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pk-med-strengthens-governance-with-gene-therapy-pioneers-ahead-of-phase-2-gout-trial 2026-07-29T16:11:07+00:00 hourly 0.9 https://trial.medpath.com/news/enzyme-based-platform-yields-novel-polyene-antifungals-with-superior-potency-and-reduced-toxicity 2026-07-29T16:11:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enzyme-based-platform-yields-novel-polyene-antifungals-with-superior-potency-and-reduced-toxicity 2026-07-29T16:11:06+00:00 hourly 0.9 https://trial.medpath.com/news/angelman-syndrome-foundation-and-citizen-health-partner-to-bring-ai-advocate-ari-to-angelman-families 2026-07-29T16:11:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/angelman-syndrome-foundation-and-citizen-health-partner-to-bring-ai-advocate-ari-to-angelman-families 2026-07-29T16:11:03+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-testing-and-sequencing-essential-in-metastatic-triple-negative-breast-cancer-expert-urges 2026-07-29T16:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genetic-testing-and-sequencing-essential-in-metastatic-triple-negative-breast-cancer-expert-urges 2026-07-29T16:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/oncolytic-virus-therapy-market-poised-for-rapid-expansion-as-precision-immunotherapy-advances 2026-07-29T16:08:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncolytic-virus-therapy-market-poised-for-rapid-expansion-as-precision-immunotherapy-advances 2026-07-29T16:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/dr-sven-k-weber-appointed-ceo-of-brain-biotech-ag-succeeding-adriaan-moelker 2026-07-29T16:08:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dr-sven-k-weber-appointed-ceo-of-brain-biotech-ag-succeeding-adriaan-moelker 2026-07-29T16:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/processa-pharmaceuticals-acquires-vidya-therapeutics-secures-200-million-financing-to-advance-next-generation-btk-inhibitor-vt-7208 2026-07-29T16:08:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/processa-pharmaceuticals-acquires-vidya-therapeutics-secures-200-million-financing-to-advance-next-generation-btk-inhibitor-vt-7208 2026-07-29T16:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/deepmind-dismantles-alphafold-team-as-nobel-laureates-exit-for-rivals-shifting-ai-drug-discovery-landscape 2026-07-29T16:08:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deepmind-dismantles-alphafold-team-as-nobel-laureates-exit-for-rivals-shifting-ai-drug-discovery-landscape 2026-07-29T16:08:17+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-beats-q2-estimates-as-rare-disease-portfolio-and-leqembi-drive-growth-raises-2026-revenue-outlook 2026-07-29T16:08:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-beats-q2-estimates-as-rare-disease-portfolio-and-leqembi-drive-growth-raises-2026-revenue-outlook 2026-07-29T16:08:12+00:00 hourly 0.9 https://trial.medpath.com/news/ems-and-bd-launch-semaglutide-therapy-in-brazil-expanding-glp-1-access-with-advanced-injection-pen-platform 2026-07-29T16:08:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ems-and-bd-launch-semaglutide-therapy-in-brazil-expanding-glp-1-access-with-advanced-injection-pen-platform 2026-07-29T16:08:07+00:00 hourly 0.9 https://trial.medpath.com/news/flinders-university-secures-9m-nhmrc-funding-for-three-centres-of-research-excellence 2026-07-29T16:07:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flinders-university-secures-9m-nhmrc-funding-for-three-centres-of-research-excellence 2026-07-29T16:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/high-thc-medicinal-cannabis-prescribing-in-australia-far-outpaces-clinical-evidence-review-finds 2026-07-29T16:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/high-thc-medicinal-cannabis-prescribing-in-australia-far-outpaces-clinical-evidence-review-finds 2026-07-29T16:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/chmp-backs-expanded-repatha-indication-for-primary-prevention-of-first-heart-attack-and-stroke 2026-07-29T15:07:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chmp-backs-expanded-repatha-indication-for-primary-prevention-of-first-heart-attack-and-stroke 2026-07-29T15:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/ractigen-therapeutics-closes-31m-financing-to-advance-sarna-pipeline-and-extrahepatic-delivery-platforms 2026-07-29T15:07:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ractigen-therapeutics-closes-31m-financing-to-advance-sarna-pipeline-and-extrahepatic-delivery-platforms 2026-07-29T15:07:26+00:00 hourly 0.9 https://trial.medpath.com/news/vivid-dx-raises-15m-seed-funding-to-advance-ai-powered-rapid-diagnostics-for-drug-resistant-infections 2026-07-29T15:07:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivid-dx-raises-15m-seed-funding-to-advance-ai-powered-rapid-diagnostics-for-drug-resistant-infections 2026-07-29T15:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/platinum-chemotherapy-leaves-lasting-genomic-scars-in-children-s-livers-study-finds 2026-07-29T15:07:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/platinum-chemotherapy-leaves-lasting-genomic-scars-in-children-s-livers-study-finds 2026-07-29T15:07:10+00:00 hourly 0.9 https://trial.medpath.com/news/nih-awards-28-2m-to-penn-state-ctsi-to-expand-rural-clinical-trial-access-and-health-research 2026-07-29T14:07:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-awards-28-2m-to-penn-state-ctsi-to-expand-rural-clinical-trial-access-and-health-research 2026-07-29T14:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/tasrif-pharmaceutical-secures-second-u-s-patent-for-cd155-targeting-antibodies-as-anti-tigit-field-contracts 2026-07-29T14:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tasrif-pharmaceutical-secures-second-u-s-patent-for-cd155-targeting-antibodies-as-anti-tigit-field-contracts 2026-07-29T14:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/red-light-holland-rebrands-to-rhelion-life-sciences-advances-naturally-derived-psilocybin-drug-pex010-toward-phase-ii-clinical-development 2026-07-29T14:07:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/red-light-holland-rebrands-to-rhelion-life-sciences-advances-naturally-derived-psilocybin-drug-pex010-toward-phase-ii-clinical-development 2026-07-29T14:07:04+00:00 hourly 0.9 https://trial.medpath.com/news/fnih-launches-landmark-map-d-study-to-redefine-depression-diagnosis-and-treatment-through-precision-medicine 2026-07-29T14:07:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fnih-launches-landmark-map-d-study-to-redefine-depression-diagnosis-and-treatment-through-precision-medicine 2026-07-29T14:07:03+00:00 hourly 0.9 https://trial.medpath.com/news/cyrano-therapeutics-cyr-064-phase-2-flavor-trial-results-to-be-featured-at-american-rhinologic-society-annual-meeting 2026-07-29T14:06:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cyrano-therapeutics-cyr-064-phase-2-flavor-trial-results-to-be-featured-at-american-rhinologic-society-annual-meeting 2026-07-29T14:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/basilea-secures-30-million-barda-tranche-to-advance-fosmanogepix-phase-iii-program-for-invasive-fungal-infections 2026-07-29T13:08:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/basilea-secures-30-million-barda-tranche-to-advance-fosmanogepix-phase-iii-program-for-invasive-fungal-infections 2026-07-29T13:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/axogen-makes-strategic-investment-in-trace-biosciences-to-advance-nerve-specific-intraoperative-imaging-technology 2026-07-29T13:07:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/axogen-makes-strategic-investment-in-trace-biosciences-to-advance-nerve-specific-intraoperative-imaging-technology 2026-07-29T13:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/shape-therapeutics-secures-mjff-grant-to-advance-shp-201-a-one-time-rna-editing-gene-therapy-for-parkinson-s-disease 2026-07-29T11:07:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shape-therapeutics-secures-mjff-grant-to-advance-shp-201-a-one-time-rna-editing-gene-therapy-for-parkinson-s-disease 2026-07-29T11:07:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-c2n-diagnostics-precivityad2-blood-test-for-alzheimer-s-in-adults-as-young-as-40 2026-07-29T11:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-c2n-diagnostics-precivityad2-blood-test-for-alzheimer-s-in-adults-as-young-as-40 2026-07-29T11:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/oral-semaglutide-reduces-heavy-drinking-in-alcohol-use-disorder-cu-anschutz-clinical-trial-results 2026-07-29T09:07:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oral-semaglutide-reduces-heavy-drinking-in-alcohol-use-disorder-cu-anschutz-clinical-trial-results 2026-07-29T09:07:24+00:00 hourly 0.9 https://trial.medpath.com/news/exploiting-rna-polymerase-vulnerabilities-a-new-strategy-against-drug-resistant-tuberculosis 2026-07-29T08:08:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exploiting-rna-polymerase-vulnerabilities-a-new-strategy-against-drug-resistant-tuberculosis 2026-07-29T08:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/study-finds-strong-link-between-cutaneous-melanoma-and-uveal-melanoma-risk 2026-07-29T08:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-finds-strong-link-between-cutaneous-melanoma-and-uveal-melanoma-risk 2026-07-29T08:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/unsw-researchers-awarded-61-million-in-nhmrc-investigator-grants-to-advance-autoimmune-oncology-and-genomics-research 2026-07-29T07:09:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unsw-researchers-awarded-61-million-in-nhmrc-investigator-grants-to-advance-autoimmune-oncology-and-genomics-research 2026-07-29T07:09:36+00:00 hourly 0.9 https://trial.medpath.com/news/yale-school-of-medicine-launches-online-master-of-health-science-in-medical-ai-to-bridge-the-clinical-technical-divide 2026-07-29T06:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yale-school-of-medicine-launches-online-master-of-health-science-in-medical-ai-to-bridge-the-clinical-technical-divide 2026-07-29T06:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/csl-to-begin-clinical-trials-for-horizon-2-immunoglobulin-manufacturing-process-following-fda-and-ema-discussions 2026-07-29T04:08:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/csl-to-begin-clinical-trials-for-horizon-2-immunoglobulin-manufacturing-process-following-fda-and-ema-discussions 2026-07-29T04:08:31+00:00 hourly 0.9 https://trial.medpath.com/news/personalised-medicine-and-parp-inhibitors-transform-stage-iv-breast-cancer-outcomes-a-decade-of-progress-in-northern-ireland 2026-07-29T01:07:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/personalised-medicine-and-parp-inhibitors-transform-stage-iv-breast-cancer-outcomes-a-decade-of-progress-in-northern-ireland 2026-07-29T01:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/spring-daylight-saving-time-linked-to-30-increased-risk-of-retinal-vascular-diseases-large-scale-study-finds 2026-07-29T00:53:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spring-daylight-saving-time-linked-to-30-increased-risk-of-retinal-vascular-diseases-large-scale-study-finds 2026-07-29T00:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/unr-med-and-renown-health-build-nevada-s-first-integrated-academic-health-system-expanding-clinical-trials-and-research-infrastructure 2026-07-28T22:12:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unr-med-and-renown-health-build-nevada-s-first-integrated-academic-health-system-expanding-clinical-trials-and-research-infrastructure 2026-07-28T22:12:37+00:00 hourly 0.9 https://trial.medpath.com/news/us-hiv-funding-cuts-slashed-new-patient-enrollment-59-across-east-africa-within-weeks 2026-07-28T22:12:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-hiv-funding-cuts-slashed-new-patient-enrollment-59-across-east-africa-within-weeks 2026-07-28T22:12:36+00:00 hourly 0.9 https://trial.medpath.com/news/uw-health-launches-proton-therapy-program-for-cancer-patients-through-clinical-trial 2026-07-28T22:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uw-health-launches-proton-therapy-program-for-cancer-patients-through-clinical-trial 2026-07-28T22:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-aacr-oncology-educational-fellowship-opens-applications-for-2026-2027-cohort 2026-07-28T22:11:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-aacr-oncology-educational-fellowship-opens-applications-for-2026-2027-cohort 2026-07-28T22:11:35+00:00 hourly 0.9 https://trial.medpath.com/news/plant-proteins-that-imitate-fiber-reprogram-gut-microbes-to-favor-healthy-metabolites 2026-07-28T21:11:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/plant-proteins-that-imitate-fiber-reprogram-gut-microbes-to-favor-healthy-metabolites 2026-07-28T21:11:10+00:00 hourly 0.9 https://trial.medpath.com/news/centene-swings-to-1-1-billion-q2-profit-as-medical-costs-stabilize-and-aca-business-rebounds 2026-07-28T20:14:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/centene-swings-to-1-1-billion-q2-profit-as-medical-costs-stabilize-and-aca-business-rebounds 2026-07-28T20:14:22+00:00 hourly 0.9 https://trial.medpath.com/news/mirae-launches-with-5-4m-to-bring-ai-driven-continuous-care-to-autoimmune-disease 2026-07-28T19:10:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mirae-launches-with-5-4m-to-bring-ai-driven-continuous-care-to-autoimmune-disease 2026-07-28T19:10:27+00:00 hourly 0.9